<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<?covid-19-tdm?>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem.</journal-id>
<journal-title>Frontiers in Chemistry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem.</abbrev-journal-title>
<issn pub-type="epub">2296-2646</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">744376</article-id>
<article-id pub-id-type="doi">10.3389/fchem.2021.744376</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemistry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Inhibition Potencies of Phytochemicals Derived from Sesame Against SARS-CoV-2 Main Protease: A Molecular Docking and Simulation Study</article-title>
<alt-title alt-title-type="left-running-head">Kumar et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Sesame Compounds Against COVID-19</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Anuj</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/238105/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mishra</surname>
<given-names>Dwijesh Chandra</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/327961/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Angadi</surname>
<given-names>Ulavappa Basavanneppa</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/498507/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yadav</surname>
<given-names>Rashmi</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1464387/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rai</surname>
<given-names>Anil</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Dinesh</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/401687/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Centre for Agricultural Bioinformatics (CABin), ICAR- Indian Agricultural Statistics Research Institute, <addr-line>New Delhi</addr-line>, <country>India</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Division of Germplasm Evaluation, ICAR-National Bureau of Plant Genetic Resources, <addr-line>New Delhi</addr-line>, <country>India</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1040562/overview">Sugunadevi Sakkiah</ext-link>, National Center for Toxicological Research (FDA), United&#x20;States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/747316/overview">Subhash Chandra</ext-link>, Kumaun University, India</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/414486/overview">Md Tabish Rehman</ext-link>, King Saud University, Saudi Arabia</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Ulavappa Basavanneppa Angadi, <email>ub.angadi@icar.gov.in</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Theoretical and Computational Chemistry, a section of the journal Frontiers in Chemistry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>744376</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>07</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>09</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Kumar, Mishra, Angadi, Yadav, Rai and Kumar.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Kumar, Mishra, Angadi, Yadav, Rai and Kumar</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>The ongoing COVID-19 pandemic, caused by SARS-CoV-2, has now spread across the nations with high mortality rates and multifaceted impact on human life. The proper treatment methods to overcome this contagious disease are still limited. The main protease enzyme (M<sup>pro</sup>, also called 3CL<sup>pro</sup>) is essential for viral replication and has been considered as one of the potent drug targets for treating COVID-19. In this study, virtual screening was performed to find out the molecular interactions between 36 natural compounds derived from sesame and the M<sup>pro</sup> of COVID-19. Four natural metabolites, namely, sesamin, sesaminol, sesamolin, and sesamolinol have been ranked as the top interacting molecules to M<sup>pro</sup> based on the affinity of molecular docking. Moreover, stability of these four sesame-specific natural compounds has also been evaluated using molecular dynamics (MD) simulations for 200 nanoseconds. The molecular dynamics simulations and free energy calculations revealed that these compounds have stable and favorable energies, causing strong binding with M<sup>pro</sup>. These screened natural metabolites also meet the essential conditions for drug likeness such as absorption, distribution, metabolism, and excretion (ADME) properties as well as Lipinski&#x2019;s rule of five. Our finding suggests that these screened natural compounds may be evolved as promising therapeutics against COVID-19.</p>
</abstract>
<kwd-group>
<kwd>COVID-19</kwd>
<kwd>main protease</kwd>
<kwd>sesame</kwd>
<kwd>natural compounds</kwd>
<kwd>molecular docking</kwd>
<kwd>molecular dynamics simulations</kwd>
<kwd>therapeutics</kwd>
</kwd-group>
<contract-num rid="cn001">BT/Ag/Network/Sesame/2019-20</contract-num>
<contract-sponsor id="cn001">Department of Biotechnology, Ministry of Science and Technology, India<named-content content-type="fundref-id">10.13039/501100001407</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The ongoing pandemic eruption due to the worldwide spread of coronavirus disease (COVID-19) is caused by the novel virus strain severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2; previously named 2019-nCoV) (<xref ref-type="bibr" rid="B115">Wu et&#x20;al., 2020b</xref>). This viral disease is an unprecedented global public health care threat (<xref ref-type="bibr" rid="B48">Jamwal et&#x20;al., 2020</xref>). The first case of COVID-19 disease was originated from Wuhan, Hubei Province, China, and quickly spread across 219 countries and territories around the world with high mortality rates in immunocompromised patients (<xref ref-type="bibr" rid="B32">Enayatkhani et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B65">Mackenzie and Smith, 2020</xref>; <xref ref-type="bibr" rid="B117">Xu et&#x20;al., 2020</xref>). Based on the recommendations of the Emergency Committee, the World Health Organization (WHO) has declared this respiratory infectious disease as a Public Health Emergency of International Concern (PHEIC) on 30 January, 2020 and a pandemic on 11 March, 2020 (<xref ref-type="bibr" rid="B94">Shi et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B120">Yu et&#x20;al., 2020</xref>). As on 10 July 2021, this contagious disease had led to more than 185,291,530 confirmed cases and 4,010,834 fatalities (<ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/">https://covid19.who.int/</ext-link>), with the number of cases increasing abruptly across the globe. At present, India is fighting hard against the second wave of COVID-19. The ongoing pandemic has now initiated taking a toll on India&#x2019;s economy. A large population of India is facing disproportionately higher rates of COVID-19 infection, morbidity, and mortality. As of 10 July 2021, the total COVID-19 caseload has now soared to 30,752,950 with 405,939 deaths (<ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/table">https://covid19.who.int/table</ext-link>). India is the most severely affected Asian country. The ongoing pandemic has been considered more dreadful than the previous global outbreaks, namely, SARS-CoV (2002&#x2013;2003) and Middle East respiratory syndrome (MERS) (2012&#x2013;present) (<xref ref-type="bibr" rid="B27">de Wit et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B41">Gupta et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B111">Wang et&#x20;al., 2020b</xref>; <xref ref-type="bibr" rid="B116">Wu and McGoogan, 2020</xref>; <xref ref-type="bibr" rid="B121">Yuan et&#x20;al., 2020</xref>). Based on previous investigations, the fatality rate of SARS-CoV and MERS has been calculated as 10 and 35%, respectively (<xref ref-type="bibr" rid="B62">Lee et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B18">Cheng et&#x20;al., 2007</xref>). It has been well-reported that COVID-19 affects the lower respiratory tract of the body, which causes pneumonia and affects the gastrointestinal system, kidney, heart, and central nervous system. Fever, cough, diarrhea, and tiredness have been considered the most common symptoms (<xref ref-type="bibr" rid="B16">Chen et&#x20;al., 2020a</xref>; <xref ref-type="bibr" rid="B100">Tang et&#x20;al., 2020</xref>), while aches and pains, sore throat, conjunctivitis, headache, loss of taste or smell, a rash on skin, or discoloration of fingers or toes are the less common symptoms of this infectious disease (<xref ref-type="bibr" rid="B9">Backer et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B88">Rothe et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B90">Russell et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B107">Verdoni et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B118">Yu and Yu, 2020</xref>).</p>
<p>The coronaviruses have been recognized as a large enveloped positive-sense single-strand RNA viruses from Nidovirales (order) of the Coronaviridae family and subfamily Coronavirinae (<xref ref-type="bibr" rid="B86">Raj et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B93">Shamsi et&#x20;al., 2021</xref>). This subfamily is classified into four genera including <italic>alpha-</italic>, <italic>beta-</italic>, <italic>gamma-</italic>, and <italic>deltacoronavirus</italic> (<italic>&#x3b1;-</italic>, <italic>&#x3b2;-</italic>, <italic>&#x3b3;-</italic>, and <italic>&#x3b4;-CoV</italic>) based on evolutionary methods (<xref ref-type="bibr" rid="B46">Hulswit et&#x20;al., 2016</xref>). In view of previous reports, coronaviruses have been considered as highly evolving viruses, with a high rate of mutation and genomic recombination (<xref ref-type="bibr" rid="B17">Chen et&#x20;al., 2020b</xref>). In the past, six species of human coronavirus associated with different respiratory tract diseases have been reported, which include HCoV-NL63, HCoV-229E, HCoV-OC34, HCoV-HKU1, SARS-CoV, and MERS-CoV (<xref ref-type="bibr" rid="B8">Arden et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B113">Woo et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B97">Su et&#x20;al., 2016</xref>). The novel strain SARS-CoV-2 has been characterized as the seventh strain of the human coronavirus. Based on the significant nucleotide sequence similarity with SARS and MERS coronaviruses, the International Committee on Taxonomy of Viruses (ICTV) coined the nomenclature of SARS-COV-2 (<xref ref-type="bibr" rid="B42">Hasan et&#x20;al., 2020</xref>). The ICTV taxonomically placed the SARS-COV-2 in the genus <italic>Betacoronavirus</italic> (<xref ref-type="bibr" rid="B43">Helmy et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B111">Wang et&#x20;al., 2020b</xref>).</p>
<p>The genome size of SARS-CoV-2 is &#x223c;29.9&#xa0;kb (29,903 nucleotides) (<xref ref-type="bibr" rid="B114">Wu et&#x20;al., 2020a</xref>). The first whole-genome sequencing data for SARS-CoV-2 (&#x223c;30&#xa0;kb) were submitted to the Genbank with the accession number MN908947 and isolated from Wuhan (<xref ref-type="bibr" rid="B114">Wu et&#x20;al., 2020a</xref>). The genome of SARS-CoV-2 encodes approximately 13&#x2013;15 open reading frames (ORFs) which are flanked by 5&#x2032; and 3&#x2032; UTRs (<xref ref-type="bibr" rid="B17">Chen et&#x20;al., 2020b</xref>; <xref ref-type="bibr" rid="B30">Elfiky and Azzam, 2020</xref>; <xref ref-type="bibr" rid="B37">Gordon et&#x20;al., 2020</xref>). These ORFs constitute a replicase assembly during the replication process of the central dogma of molecular biology and encode 27 distinct structural and non-structural proteins (NSPs) (<xref ref-type="bibr" rid="B64">Liu et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B93">Shamsi et&#x20;al., 2021</xref>). The 5&#x2032; end of the SARS-CoV-2 genome encodes 16 NSPs (Nsp1-16) and constitutes the replicase/transcriptase complex (RTC). These 16 proteins are conserved in all SARS viruses and play a critical role in a set of biological processes such as viral replication, assembly, and immune response modulation (<xref ref-type="bibr" rid="B93">Shamsi et&#x20;al., 2021</xref>). The 3&#x2032; end of the viral genome encodes four conical structural proteins including E (envelope protein), M (membrane protein), N (nucleocapsid protein), and S (spike protein), and nine putative accessory factors. The main protease enzyme (M<sup>pro</sup> also called 3CL<sup>pro</sup>) is essential for viral replication and has been considered as one of the potent drug targets for treating COVID-19 (<xref ref-type="bibr" rid="B51">Joshi et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B54">Khan et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B58">Kumar et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B80">Pant et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B114">Wu et&#x20;al., 2020a</xref>; <xref ref-type="bibr" rid="B122">Zhang et&#x20;al., 2020</xref>). In cooperation with other components, this important enzyme also helps in the transcription of the viral RNA. M<sup>pro</sup> is a key enzyme that exclusively cleaves the polyproteins (pp1a and pp1ab) which is essential for the assembly of virus drugs (<xref ref-type="bibr" rid="B50">Jin et&#x20;al., 2020</xref>). The molecular mass of M<sup>pro</sup> is 33,797&#xa0;Da with length of 306 amino acid residues and structurally possesses the three functional domains, namely, domain I (8&#x2013;101 residues), domain II (102&#x2013;184 residues), and domain III (201&#x2013;306 residues) (<xref ref-type="bibr" rid="B50">Jin et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B54">Khan et&#x20;al., 2020</xref>). Among them, domains I and II have an antiparallel &#x3b2;-barrel structure, while domain III represents a group of five &#x3b1;-helices organized as a large antiparallel cluster. Domain III is connected to domain II by a 15-residue-long loop region (185&#x2013;200 residues). The active site is composed of a catalytic dyad having Cys145 and His41 residues (<xref ref-type="bibr" rid="B54">Khan et&#x20;al., 2020</xref>). The functional role of M<sup>pro</sup> in the viral replication highlights its importance that can be used to identify the potential drug therapeutics against COVID-19 (<xref ref-type="bibr" rid="B103">Ullrich and Nitsche, 2020</xref>). Solved crystal structures of M<sup>pro</sup> provide a platform to develop and design the antiviral drugs to combat COVID-19 (<xref ref-type="bibr" rid="B50">Jin et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B122">Zhang et&#x20;al., 2020</xref>). In response to the COVID-19 outbreak, several studies have been performed using integrated bioinformatics and molecular modeling approaches for the screening of novel natural metabolites as potential drug targets against M<sup>pro</sup> (<xref ref-type="bibr" rid="B19">Chikhale et&#x20;al., 2020a</xref>; <xref ref-type="bibr" rid="B58">Kumar et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B69">Maurya and Sharma, 2020</xref>; <xref ref-type="bibr" rid="B89">Rout et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B102">Tripathi et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B71">Mishra et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B87">Romeo et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B101">Tock et&#x20;al., 2021</xref>). But no effective method has been developed yet to prevent and treat the COVID-19 disease in a significant manner. In addition to the aforementioned approaches, several other viral protease inhibitors like remdesivir, hydroxychloroquine, chloroquine, lopinavir, ritonavir, oseltamivir, and fapilavir have been explored as repurposed drugs for COVID-19 treatment (<xref ref-type="bibr" rid="B14">Chang et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B15">Chang et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B22">Contini, 2020</xref>; <xref ref-type="bibr" rid="B26">Das et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B31">Elfiky, 2020</xref>; <xref ref-type="bibr" rid="B36">Gonzalez&#x2013;Paz et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B47">Islam et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B54">Khan et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B96">Sinha et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B109">Wahedi et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B2">Abdelli et&#x20;al., 2021</xref>). The antimalarial drug named as chloroquine has been proposed as the potential inhibitor of M<sup>pro</sup> activity (<xref ref-type="bibr" rid="B78">Ou et&#x20;al., 2021</xref>). In a recent follow-up study, <xref ref-type="bibr" rid="B84">Pathak et&#x20;al. (2021)</xref> explored the potential of rifampicin and letermovir as repurposed drug candidates against COVID-19. On the contrary, several studies reported the severe adverse effects of these repurposed drugs in different countries (<xref ref-type="bibr" rid="B98">Sultana et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B110">Wang et&#x20;al., 2020a</xref>). Therefore, it is imperative to discover natural compound&#x2013;based drug targets that could serve as potential inhibitors of different SARS-CoV-2 proteins and aid in controlling viral replication to enhance efficacy in COVID-19 treatment.</p>
<p>Sesame (<italic>Sesamum indicum</italic> L.) is an herbaceous annual plant cultivated for its edible seed, oil, and flavorsome value, belonging to the order Tubiflorae, family Pedaliaceae with many common names including gingelly, til, and benne seed (<xref ref-type="bibr" rid="B12">Bhat et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B83">Pathak et&#x20;al., 2019</xref>). This oil crop is regarded as &#x201c;queen of oilseeds&#x201d; because of its property of resistance to oxidation and rancidity (<xref ref-type="bibr" rid="B24">Dalibalta et&#x20;al., 2020</xref>). Sesame is widely cultivated in the tropical parts of Africa and Asia, India being one of the major producers with Myanmar, China, and Sudan (<xref ref-type="bibr" rid="B67">Majdalawieh et&#x20;al., 2017</xref>). A plethora of nutrients including proteins, carbohydrates, antioxidants, lignans, tocopherols, phytates, phytosterols, and polyunsaturated fatty acids are exclusively found in sesame (<xref ref-type="bibr" rid="B76">Nagendra Prasad et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B59">Kumar et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B83">Pathak et&#x20;al., 2019</xref>). These bioactive compounds possess certain medicinal properties like hepatoprotective, hypoglycemic, antihypertensive, anti-estrogenic, and anticancer (<xref ref-type="bibr" rid="B66">Kumar and Singh, 2014</xref>; <xref ref-type="bibr" rid="B67">Majdalawieh et&#x20;al., 2017</xref>). Active ingredients of sesame have also been investigated as potential inhibitors of Parkinson&#x2019;s disease (PD) (<xref ref-type="bibr" rid="B53">Kappo et&#x20;al., 2016</xref>). There are very few reports available for the screening of sesame-derived compounds against main protease of COVID-19. So far, only one compound of sesame, namely, sesamin has been well-explored against COVID-19 using <italic>in silico</italic> approach. <xref ref-type="bibr" rid="B56">Kodchakorn et&#x20;al. (2020)</xref> investigated the potential of sesamin along with other herbal medicines (andrographolide, anthocyanin-b-D-glucoside, capsaicin, curcumin, cyanidin, cyanidin-3-O-glucoside, and hesperidin) against the M<sup>pro</sup> of SARS-CoV-2 using molecular docking. Docking complexes of these nutraceuticals with M<sup>pro</sup> were further validated for their atomic stability using molecular dynamics (MD) simulations on 50 ns, and suggested that the screened compounds may be considered for coprotection and treatment against COVID-19. In a recent study, <xref ref-type="bibr" rid="B79">Pandey and Verma (2020)</xref> also studied the potential of sesamin and four other dietary components (galangin, ellagic acid, capsaicin, and epicatechin) as structural inhibitors of SARS-CoV-2&#x20;M<sup>pro</sup> using the molecular docking approach. In a very recent study, <xref ref-type="bibr" rid="B7">Allam et&#x20;al. (2021)</xref> reported seven sesame-derived natural compounds (sesamin, sesamolin, pinoresinol, hydroxymatairesinol, spicatolignan, ferulic acid, and vanillic acid) as potential inhibitors against three proteins of SARS-CoV-2 including M<sup>pro</sup>, papain-like protease (PL<sup>pro</sup>), and the RNA-dependent RNA polymerase (RdRp) using the molecular docking analysis followed by MD simulations on 50&#xa0;ns for representative complexes. However, there is no significant evidence of docking results evaluation available for&#x20;MD simulations on high nanosecond scale (up to 200&#xa0;ns) to&#x20;understand the inhibitory mechanism of all sesame-derived compounds against the SARS-CoV-2 proteins. Despite the medicinal importance of sesame, all bioactive molecules derived from this important medicinal plant have not been well-explored in a significant manner yet for the treatment of COVID-19. With the fruitful utilization of molecular modeling methods including molecular docking and MD simulations, sesame-derived bioactive compounds may be utilized to design the alternative natural compound&#x2013;based effective therapeutics against COVID-19.</p>
<p>Keeping this in view, in the present study, we have undertaken a thorough attempt to investigate the inhibition potencies of 36 phytochemicals from sesame against M<sup>pro</sup> of SARS-CoV-2 using the molecular docking approach. Four natural metabolites, namely, sesamin, sesaminol, sesamolin, and sesamolinol, were further subjected to conformational stability using MD simulations followed by free energy calculations. The knowledge generated in the current study encourages and suggests that the sesame-derived phytochemicals have enough potential of being effective in treatment of COVID-19.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<p>A flowchart depicting the pipeline involved in the identification of interaction between sesame-derived bioactive molecules and M<sup>pro</sup> is presented in <xref ref-type="fig" rid="F1">Figure&#x20;1</xref>.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Representation of pipeline utilized in the present study to identify the inhibitors of M<sup>pro</sup> of SARS-CoV-2 using an extensive molecular modeling approach.</p>
</caption>
<graphic xlink:href="fchem-09-744376-g001.tif"/>
</fig>
<sec id="s2-1">
<title>Ligand Selection</title>
<p>An extensive literature survey was conducted to prepare a library of sesame-derived natural compounds reported with therapeutic potential. Chemical structures of 36 phytochemicals (<xref ref-type="sec" rid="s10">Supplementary Table S1</xref>) were obtained from the PubChem database (<xref ref-type="bibr" rid="B55">Kim et&#x20;al., 2020</xref>) in a Spatial Data File (SDF) format. All these molecules were optimized prior to molecular docking using a set of AutoDock tools (<xref ref-type="bibr" rid="B74">Morris et&#x20;al., 2009</xref>). Each and every molecule embedded in thse library was prepared with the addition of polar hydrogens and Gasteiger charges calculation. For the docking purpose, the molecules were saved in a pdbqt format using PyRx Open Babble tools (<xref ref-type="bibr" rid="B77">O&#x27;Boyle et&#x20;al., 2011</xref>).</p>
</sec>
<sec id="s2-2">
<title>Preparation of Receptor</title>
<p>The crystal structure of the M<sup>pro</sup> of SARS-CoV-2 in a complex with Z45617795 (PDB ID: 5R7Y) was attained from the RCSB-Protein Data Bank (<xref ref-type="bibr" rid="B11">Berman, 2000</xref>; <xref ref-type="bibr" rid="B13">Burley et&#x20;al., 2018</xref>) for docking purposes. This protein crystal structure was solved by the PanDDA analysis group (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/5R7Y">https://www.rcsb.org/structure/5R7Y</ext-link>). Preprocessing of the M<sup>pro</sup> of SARS-CoV-2 was carried out by removing water atoms and heteroatoms, and adding polar hydrogen atoms and Kollman charges on it using AutoDockTools version 1.5.6. Swiss-pdb Viewer (<xref ref-type="bibr" rid="B39">Guex and Peitsch, 1997</xref>) was employed to structure optimization and energy minimization. The clean geometry module available in the Discovery Studio platform was utilized for the side chain correction.</p>
</sec>
<sec id="s2-3">
<title>Virtual Screening Based on Molecular Docking</title>
<p>In a search for a drug against COVID-19, we performed a site-specific docking screen for the M<sup>pro</sup> of SARS-CoV-2 against the&#x20;prepared library of sesame-derived natural compounds containing 36 compounds. AutoDock Vina program was employed for virtual screening. The grid box was created with the size of 70&#xa0;&#xc5; &#xd7; 70&#xa0;&#xc5; &#xd7; 70&#xa0;&#xc5;, with a total of 50 genetic run. For the purpose of docking, amino acid residues such as Thr24, Thr26, Asn119, Phe140, Gly143, Cys145, His163, His164, Glu166, Gln189, and Thr190 were considered as active sites, as earlier reported by <xref ref-type="bibr" rid="B54">Khan et&#x20;al. (2020)</xref> and <xref ref-type="bibr" rid="B58">Kumar et&#x20;al. (2020)</xref>. Other parameters were set as default while docking process. The carmofur (CID_2577) compound was selected as the positive control (<xref ref-type="bibr" rid="B50">Jin et&#x20;al., 2020</xref>) for docking process. After docking, the top ranked compounds (based on docking score, number of hydrogen bonds, and specificity) (<xref ref-type="table" rid="T1">Table1</xref>) were chosen and visually inspected using PyMol and Discovery Studio (<xref ref-type="bibr" rid="B28">DeLano, 2002</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>List of top four natural compounds shortlisted based on binding energy score as a result of virtual screening.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">S. No.</th>
<th align="left">Compound</th>
<th align="center">2D structure</th>
<th align="center">Binding energy (kcal/mol)</th>
<th align="center">Molecular interactions</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td align="left">M<sup>pro</sup> (active site residues)</td>
<td colspan="3" align="left">Thr24, Thr26, Asn119, Phe140, Gly143, Cys145, His163, His164, Glu166, Gln189, and Thr190</td>
</tr>
<tr>
<td rowspan="4" align="left">2</td>
<td rowspan="4" align="left">Sesamin (CID_72307)</td>
<td rowspan="4" align="left">
<inline-graphic xlink:href="fchem-09-744376-fx1.tif"/>
</td>
<td rowspan="4" align="center">&#x2212;6.7</td>
<td align="left">Hydrogen bond: ASN151 (5.46&#xa0;&#xc5;), SER158 (4.38&#xa0;&#xc5;), and ARG298 (6.05&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Carbon&#x2013;hydrogen bond: ASP295 (5.38&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Alkyl: VAL104 (5.27&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Pi&#x2013;sigma: VAL104 (4.29&#xa0;&#xc5;)</td>
</tr>
<tr>
<td rowspan="3" align="left">3</td>
<td rowspan="3" align="left">Sesaminol (CID_94672)</td>
<td rowspan="3" align="left">
<inline-graphic xlink:href="fchem-09-744376-fx2.tif"/>
</td>
<td rowspan="3" align="center">&#x2212;6.6</td>
<td align="left">Hydrogen bond: ARG105 (6.59&#xa0;&#xc5;), ASN151 (5.39&#xa0;&#xc5;), and ARG298 (6.05&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Carbon&#x2013;hydrogen bond: ASP295 (5.27&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Pi-Sigma: VAL104 (4.30&#xa0;&#xc5;)</td>
</tr>
<tr>
<td rowspan="2" align="left">4</td>
<td rowspan="2" align="left">Sesamolin (CID_131801617)</td>
<td rowspan="2" align="left">
<inline-graphic xlink:href="fchem-09-744376-fx3.tif"/>
</td>
<td rowspan="2" align="center">&#x2212;6.4</td>
<td align="left">Hydrogen bond: ARG105 (6.03&#xa0;&#xc5;), GLN110 (4.52&#xa0;&#xc5;), and SER158 (4.08&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Pi&#x2013;sigma: VAL104 (4.89&#xa0;&#xc5;)</td>
</tr>
<tr>
<td rowspan="5" align="left">5</td>
<td rowspan="5" align="left">Sesamolinol (CID_443019)</td>
<td rowspan="5" align="left">
<inline-graphic xlink:href="fchem-09-744376-fx4.tif"/>
</td>
<td rowspan="5" align="center">&#x2212;6.1</td>
<td align="left">Hydrogen bond: SER158 (4.10&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Carbon&#x2013;hydrogen bond: ILE106 (4.45&#xa0;&#xc5;), and GLN110 (5.21&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Pi&#x2013;sigma: VAL104 (5.04&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Alkyl: VAL202 (5.45&#xa0;&#xc5;), and ILE249 (5.21&#xa0;&#xc5;)</td>
</tr>
<tr>
<td align="left">Pi-Alkyl: HIS246 (5.26&#xa0;&#xc5;)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-4">
<title>Drug-Likeness and Absorption, Distribution, Metabolism, and Excretion Profiling</title>
<p>The automated Swiss ADME server (<xref ref-type="bibr" rid="B23">Daina et&#x20;al., 2017</xref>) was employed to calculate the drug-likeness attributes of screened molecules. Different molecular properties such as molecular weight, number of hydrogen bond accepters, number of hydrogen bond donors, number of rotatable bonds, molar refractivity, bioavailability score, synthetic accessibility, TPSA, and solubility were calculated with utilizing Lipinski&#x2019;s rule of five (<xref ref-type="bibr" rid="B63">Lipinski, 2004</xref>) and Veber&#x2019;s rule (<xref ref-type="bibr" rid="B106">Veber et&#x20;al., 2002</xref>).</p>
</sec>
<sec id="s2-5">
<title>Molecular Dynamics Simulations</title>
<p>In order to assess the stabilities of docking conformation complexes of the four bioactive compounds sesamin, sesaminol, sesamolin, and sesamolinol with SARS-CoV-2&#x20;M<sup>pro</sup>, MD simulations were performed using GROMOS9643a1 force field embedded in GROMACS 5.1.1 package installed on Linux-based workstation (<xref ref-type="bibr" rid="B4">Abraham et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B61">Kutzner et&#x20;al., 2019</xref>). For the MD simulations, we followed the protocol previously described by <xref ref-type="bibr" rid="B35">Gajula et&#x20;al. (2016)</xref> and <xref ref-type="bibr" rid="B49">Jee et&#x20;al. (2017)</xref>. The automatic PRODRG server was employed to prepare the topology files of ligand molecules (<xref ref-type="bibr" rid="B92">Sch&#xfc;ttelkopf and van Aalten, 2004</xref>). The docking complexes were solvated in a dodecahedron box. In order to make the whole system neutral, the appropriate Na&#x2b; ions were added to the system. The steepest descent algorithm was applied to perform the energy minimization of the prepared system with 50,000 iteration steps and cutoff up to 1,000 kjmol<sup>&#x2212;1</sup> with a primary goal of reducing the steric clashes during simulations. The long-range electrostatic interactions were calculated by using particle mesh Ewald (PME) truncation method (<xref ref-type="bibr" rid="B3">Abraham and Gready, 2011</xref>). Prior to a production run, the process of equilibrium was completed in two phases. In the first phase, equilibration was established with a constant number of particles, volume, and temperature (NVT), with each step 2 femtosecond (fs). The second phase was performed with a constant number of particles, pressure, and temperature NPT, with the ensemble at 300&#xa0;K. After determining the coordinates, LINCS algorithm was considered to constrain the covalent bonds involving hydrogen atoms (<xref ref-type="bibr" rid="B44">Hess et&#x20;al., 1997</xref>; <xref ref-type="bibr" rid="B45">Hess, 2007</xref>). Temperature was regulated inside the box using V-rescale, a popular Berendsen temperature coupling method. Finally, a production run of 200&#xa0;ns was run with each step of 2&#xa0;fs.</p>
</sec>
<sec id="s2-6">
<title>Trajectory Analysis</title>
<p>After the successful completion of MD simulations, trajectories were analyzed using a set of tools implemented in GROMACS package. The gRMS tool of GROMACS was utilized to calculate the root-mean-square deviation (RMSD) variation in protein backbone, while the overall root-mean-square fluctuation (RMSF) in the atomic positions of protein C backbone was generated by using the grmsf module. The gyrate, gmxsasa, and g&#xa0;h bond tools were employed to estimate the radius of gyration (Rg), solvent accessible surface area (SASA), and hydrogen bonds, respectively.</p>
</sec>
<sec id="s2-7">
<title>Molecular Mechanic/Poisson&#x2013;Boltzmann Surface Area Binding Free Energy Calculations</title>
<p>The Molecular Mechanic/Poisson&#x2013;Boltzmann Surface Area (MM/PBSA) was performed on g mmpbsa script program to calculate the binding free energy of interactions between the docking complexes (<xref ref-type="bibr" rid="B60">Kumari et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B6">Aldeghi et&#x20;al., 2017</xref>). After the simulation of docking complexes, all the trajectories of 200 ns were used for MM/PBSA-based binding free energy analysis. The major energy components such as binding energy (kJ/mol), van der Waals energy (DEvdW), electrostatic energy, polar solvation energy, and SASA energy all together contributed to calculate the MM/PBSA relative binding affinity. The MM/PBSA method&#x2013;based binding free energy of the protein&#x2013;ligand systems were calculated using the following equation:<disp-formula id="equ1">
<mml:math id="m1">
<mml:mrow>
<mml:mi mathvariant="italic">&#x394;</mml:mi>
<mml:msub>
<mml:mtext>G</mml:mtext>
<mml:mrow>
<mml:mtext>MMPBSA</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mtext>&#xa0;</mml:mtext>
<mml:mo>&#x3d;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mrow>
<mml:mo>&#x2329;</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mtext>G</mml:mtext>
<mml:mrow>
<mml:mtext>complex</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mo>&#x2212;</mml:mo>
<mml:mtext>&#x2009;</mml:mtext>
<mml:msub>
<mml:mtext>G</mml:mtext>
<mml:mrow>
<mml:mtext>protein</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mo>&#x2212;</mml:mo>
<mml:mtext>&#x2009;</mml:mtext>
<mml:msub>
<mml:mtext>G</mml:mtext>
<mml:mrow>
<mml:mtext>ligand</mml:mtext>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mo>&#x232a;</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mrow>
<mml:mtext>complex</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
</disp-formula>where <italic>G</italic>
<sub>
<italic>complex</italic>
</sub> represents the total free energy of the docking complex, and <italic>G</italic>
<sub>
<italic>protein</italic>
</sub> and <italic>G</italic>
<sub>
<italic>ligand</italic>
</sub> depict the total free energies of the isolated protein and ligand in the solvent, respectively.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and Discussion</title>
<sec id="s3-1">
<title>Molecular Docking</title>
<p>Molecular docking is one of the most applied methods in the process of computer-aided drug design (CADD) to identify potential inhibitors against various pathogens. With this revolutionary method, an immense amount of energy, time, and costs of the drug discovery process can be saved to screen the large drug libraries for the discovery of potential drug compounds (<xref ref-type="bibr" rid="B108">Wadood et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B119">Yu and MacKerell, 2016</xref>). There is no effective cure for COVID-19 so far; therefore, identification of potential drug compounds is required on an urgent basis. In the present study, we screened an in-house library of sesame-derived bioactive molecules against M<sup>pro</sup> of SARS-CoV-2 using a molecular docking approach. In total, 36 natural compounds (<xref ref-type="sec" rid="s10">Supplementary Table S1</xref>) were docked into the binding pocket of M<sup>pro</sup>. The docking results demonstrated that out of 36 selected natural compounds used in the present study, four bioactive molecules, namely, sesamin, sesaminol, sesamolin, and sesamolinol were found to have a higher binding energy of &#x2212;6.7, &#x2212;6.6, &#x2212;6.4, and &#x2212;6.1 kcal/mol<sup>&#x2212;1</sup>, respectively, than the positive control compound carmofur whose binding energy was determined to be &#x2212;5.2 kcal/mol<sup>&#x2212;1</sup>. These four natural compounds (sesamin, sesaminol, sesamolin, and sesamolinol) ranked as top interacting with M<sup>pro</sup> based on the affinity of molecular docking, number of hydrogen bonds and compound specificity.</p>
<p>The 2D structures, binding score, and details of interactions of the top four screened compounds are displayed in <xref ref-type="table" rid="T1">Table&#x20;1</xref>. Docking complexes of these natural metabolites with M<sup>pro</sup> have been considered for further evaluation using MD simulations and MM/PBSA energy calculations. Discovery studio and PyMOL programs were employed to prepare the two- and three-dimensional plots of molecular interaction networks, respectively. After visualizing the 2D and 3D interaction plots, it was observed that the sesamin compound formed hydrogen bonds with three residues, namely, Asn151 (5.46&#xa0;&#xc5;), Ser158 (4.38&#xa0;&#xc5;), and Arg298 (6.05&#xa0;&#xc5;). This compound was found to have one carbon&#x2013;hydrogen (C&#x2013;H) bond with Asp295 (5.38&#xa0;&#xc5;), alkyl bond with Val104 (5.27&#xa0;&#xc5;), and Pi&#x2013;sigma bond with Val104 (4.29&#xa0;&#xc5;) residue. It also manifests van der Waals (VdW) interaction with six residues including Arg105, Ile106, Gln110, Thr111, Thr292, and Phe294 (<xref ref-type="fig" rid="F2">Figure&#x20;2</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>2D and 3D representation of molecular interaction between the M<sup>pro</sup> of COVID-19 (PDB ID: 5R7Y) and sesamin compound (CID_72307): <bold>(A)</bold> 3D structure presentation of sesamin; <bold>(B)</bold> Molecular docking complex of a crystal structure of M<sup>pro</sup> with sesamin molecule, docked using AutoDock implemented in PyRx package; <bold>(C)</bold> close view of pocket with sesamin structure in the stick model colored by atom types, yellow dashed lines represent the hydrogen bond networks; <bold>(D)</bold> 2D representation of different types of interactions with sesamin including van der Waals, conventional hydrogen bond, carbon hydrogen bond, Pi&#x2013;sigma, and alkyl; <bold>(E)</bold> hydrophobicity surface representation of the overall structure of Mpro in complex with Sesamin; and <bold>(F)</bold> pocket view of sesamin binding with M<sup>pro</sup> and the representation of residues involved in hydrogen bond donor acceptor. The docking complex of M<sup>pro</sup> with sesamin was rendered in different CPK using UCSF Chimera, Discovery Studio, and PyMol.</p>
</caption>
<graphic xlink:href="fchem-09-744376-g002.tif"/>
</fig>
<p>In the case of sesaminol, three residues, namely, Arg105 (6.59&#xa0;&#xc5;), Asn151 (5.39&#xa0;&#xc5;), and Arg298 (6.05&#xa0;&#xc5;), formed the hydrogen bonds. Residues Asp295 (5.27&#xa0;&#xc5;) and Val104 (4.30&#xa0;&#xc5;) interacted via C&#x2013;H bond and Pi&#x2013;sigma, respectively. Five residues including Ile106, Gln110, Thr111, Thr292, and Phe294 manifest VdW interaction (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>). As shown in <xref ref-type="fig" rid="F3">Figure&#x20;3B</xref>, sesamolin molecule exhibits the hydrogen bond with three residues, namely, Arg105 (6.03&#xa0;&#xc5;), Gln110 (4.52&#xa0;&#xc5;), and Ser158 (4.08&#xa0;&#xc5;), and one Pi&#x2013;sigma with Val104 (4.89&#xa0;&#xc5;). VdW interaction with residues Phe8, Lys102, Phe103, Thr111, Asn151, Thr292, and Phe294 was also formed. In the sesamolinol molecule, one residue Ser158 (4.10&#xa0;&#xc5;) formed hydrogen bond (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>). Several other residues formed other types of molecular interactions such as Ile106 (4.45&#xa0;&#xc5;), Gln110 (5.21&#xa0;&#xc5;) (C&#x2013;H bond), Val104 (5.04&#xa0;&#xc5;) (Pi&#x2013;sigma), Val202 (5.45&#xa0;&#xc5;), Ile249 (5.21&#xa0;&#xc5;) (alkyl), His246 (5.26&#xa0;&#xc5;) (Pi&#x2013;alkyl), and residues Arg105, Gln107, Asn151, Asp245 demonstrated VdW interactions.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>2D and 3D representation of docking complexes: <bold>(A)</bold> M<sup>pro</sup> and sesaminol complex; <bold>(B)</bold> M<sup>pro</sup> and sesamolin complex; <bold>(C)</bold> M<sup>pro</sup> and sesamolinol complex visualized using UCSF Chimera and Discovery Studio.</p>
</caption>
<graphic xlink:href="fchem-09-744376-g003.tif"/>
</fig>
<p>Consistent with previous studies which reported the potential inhibitors of M<sup>pro</sup> (<xref ref-type="bibr" rid="B81">Park et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B1">Aanouz et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B10">Bello et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B20">Chikhale et&#x20;al., 2020b</xref>; <xref ref-type="bibr" rid="B57">Krupanidhi et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B68">Matveeva et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B75">Muhammad et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B102">Tripathi et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B72">Mitra et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B85">Prasanth et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B105">Varadharajan et&#x20;al., 2021</xref>), in our study, screened four compounds (sesamin, sesaminol, sesamolin, and sesamolinol) were found to be tightly fit into the binding pocket of the M<sup>pro</sup> of COVID-19. In previous studies, the potential of herb-derived natural compounds have been explored to inhibit the M<sup>pro</sup> of COVID-19 using integrated bioinformatics and molecular modeling approaches (<xref ref-type="bibr" rid="B58">Kumar et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B99">Suravajhala et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B40">Gunda et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B71">Mishra et&#x20;al., 2021</xref>). Three natural metabolites, namely, ursolic acid, carvacrol, and oleanolic acid have been reported as the potential inhibitors of M<sup>pro</sup> of COVID-19. The molecular docking study of ursolic acid, carvacrol, and oleanolic acid with the M<sup>pro</sup> protein demonstrated the binding energy of &#x2212;5.9, &#x2212;4.0, and &#x2212;6.0&#xa0;kcal/mol, respectively (<xref ref-type="bibr" rid="B58">Kumar et&#x20;al., 2020</xref>). The ursolic acid formed a strong hydrogen bond with Ser46 residues, while the docking study of carvacrol and oleanolic acid with the M<sup>pro</sup> protein exhibits hydrogen bonding with Gly143 and Gln189 residues of the active site, respectively. In a recent study, <xref ref-type="bibr" rid="B40">Gunda et&#x20;al. (2021)</xref> proposed the natural xanthone compounds as promising drug inhibitors against the M<sup>pro</sup> of COVID-19 based on their significant antiviral power, which is well-documented in literatures. In a recent follow-up study, <xref ref-type="bibr" rid="B71">Mishra et&#x20;al. (2021)</xref> explored a set of natural compounds to investigate their binding potential to the M<sup>pro</sup> of COVID-19. Based on the docking and MD simulations, the four natural compounds, namely, amentoflavone, guggulsterone, puerarin, and piperine have been reported as antiviral compounds against the M<sup>pro</sup>&#x20;of COVID-19. The binding affinity of these natural metabolites with M<sup>pro</sup> protein confirms the results of the present&#x20;study.</p>
<p>Several compounds of sesame possess the natural antibacterial, antifungal, antiviral, and anti-inflammatory properties, and lignans such as sesamin, sesaminol, sesamolin, and sesamolinol are good examples (<xref ref-type="bibr" rid="B104">Uncu et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B29">Dravie et&#x20;al., 2020</xref>). Sesamin is exclusively found in the sesame plant, and its antioxidant, antibacterial, antiviral, and antifungal activities are well-reported. <xref ref-type="bibr" rid="B56">Kodchakorn et&#x20;al. (2020)</xref> identified that sesamin interacts with the M<sup>pro</sup> of SARS-CoV-2 and affects the thermal stability of M<sup>pro</sup> using in&#x20;silico methods, providing evidence for sesamin as a structural inhibitor against the M<sup>pro</sup> of SARS-CoV-2. Other studies also indicated that the sesamin compound might interact with amino acid residues Ser144, Cys145, Gln189, and Gln192 and showed significant interactions with effective residues His41, Met49, and Met165 of the M<sup>pro</sup> of COVID-19 (<xref ref-type="bibr" rid="B79">Pandey and Verma, 2020</xref>). In a follow-up study, <xref ref-type="bibr" rid="B7">Allam et&#x20;al. (2021)</xref> explored the sesamin and sesamolin compounds along with other natural compounds against M<sup>pro</sup>, PL<sup>pro</sup>, and RdRp proteins. Sesamin was found to be interacted with M<sup>pro</sup> with three residues including Gln189, Thr190, and His41, while the sesamolin molecule was reported to interact with two amino acid residues, namely, Gln189 and Thr190. Our results may support the previous findings on the inhibitory effect of sesamin and sesamolin against the M<sup>pro</sup> of COVID-19. Previous reports demonstrated the docking results only for few compounds including sesamin and sesamolin but did not consider all compounds of sesame reported in the literature, which have significant medicinal properties as well. In the present study, we explored the potential of 36&#x20;sesame-derived natural compounds against the M<sup>pro</sup> of COVID-19, and based on the docking results, the four natural compounds were selected, namely, sesamin, sesaminol, sesamolin, and sesamolinol for further evaluation using MD simulations on 200&#xa0;ns. The previous studies lack the evidence of docking results evaluated using MD simulations on high ns scale. The screened natural compounds based on the present study were also well-studied for their central role in different biological activities. Several <italic>in&#x20;vitro</italic> and <italic>in vivo</italic> studies illustrate the neuroprotective role of sesamin against cerebral ischemia (<xref ref-type="bibr" rid="B21">Chung et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B25">Dar and Arumugam, 2013</xref>). Also, this major lignin compound has demonstrated other biological activities such as antihypertensive, atherosclerosis, thrombosis, antidiabetic, anticancer, cardiovascular, and anti-inflammatory (<xref ref-type="bibr" rid="B59">Kumar et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B24">Dalibalta et&#x20;al., 2020</xref>). Of note, sesamin has been previously shown to be effective against swine flu (influenza type A H1N1) through in&#x20;silico and <italic>in&#x20;vitro</italic> studies (<xref ref-type="bibr" rid="B34">Fanhchaksai et&#x20;al., 2015</xref>). This compound was established as a novel inhibitor of pro-inflammatory cytokines, IL-1&#x3b2; and TNF-&#x3b1;. Sesaminol is one type of sesame lignan compound commonly found in sesame seeds and well known for its strong antioxidant and anticancer properties (<xref ref-type="bibr" rid="B73">Miyahara et&#x20;al., 2001</xref>; <xref ref-type="bibr" rid="B112">Watanabe et&#x20;al., 2017</xref>). Using <italic>in&#x20;vitro</italic> and <italic>in vivo</italic> models, <xref ref-type="bibr" rid="B52">Kaji et&#x20;al. (2020)</xref> reported the preventive effect of sesaminol on a neurodegenerative disease named as Parkinson&#x2019;s disease (PD). Sesamolin, the second major lignan, found in sesame oil has been regarded as a natural therapeutic agent because of its various therapeutic properties (<xref ref-type="bibr" rid="B70">Michailidis et&#x20;al., 2019</xref>). Free radical scavenging activity of sesamolin provides protection to neuronal hypoxia (<xref ref-type="bibr" rid="B82">Park et&#x20;al., 2010</xref>). Sesamolinol has also been considered the important lignin compound due to its various biological activities (<xref ref-type="bibr" rid="B38">Grougnet et&#x20;al., 2011</xref>). The present study reported bioactive molecules (sesaminol, sesamolin, and sesamolinol) which are established as potential inhibitors of M<sup>pro</sup> having enough bibliographical research support.</p>
</sec>
<sec id="s3-2">
<title>Evaluation of Drug Likeness</title>
<p>Prior to conducting MD simulation analysis, we evaluated the pharmacokinetic properties of the screened compounds of sesame. The ADME results of the shortlisted molecules calculated using SWISSADME server are shown in <xref ref-type="table" rid="T2">Table&#x20;2</xref>. Sesamin, sesaminol, sesamolin, and sesamolinol have the following molecular weights, respectively: 354.35, 370.35, 370.35, and 372.37&#xa0;g/mol; these four natural compounds have a molecular weight &#x2264;500&#xa0;g/mol, which indicated that these screened natural compounds may easily be transported, diffused, and absorbed by the body (<xref ref-type="bibr" rid="B123">Lipinski et&#x20;al., 2001</xref>; <xref ref-type="bibr" rid="B63">Lipinski, 2004</xref>).The LogP values of sesamin, sesaminol, sesamolin, and sesamolinol molecules were found to have 2.79, 2.37, 2.74, and 2.56, respectively, which are in accordance with Lipinski&#x2019;s rule of five. For these four compounds, the number of hydrogen bond donors was less than five, which meets the criteria of ADME as the number of H bond donors should be &#x2264;5. The ADME analysis revealed that sesamin, sesaminol, sesamolin, and sesamolinol molecules present the following values of the topological polar surface (TPSA): 55.38, 75.61, 64.61, and 75.61&#xa0;&#xc5;2. The range of lower TPSA values represents the acceptable results, as described by <xref ref-type="bibr" rid="B5">Ahuja et&#x20;al. (2021)</xref> and <xref ref-type="bibr" rid="B95">Singh et&#x20;al. (2021)</xref> in previous studies. It has been noted that the natural compounds derived from sesame are better behaved than the co-crystallized molecule. These screened molecules also validate Veber&#x2019;s rule which state the oral bioavailability of drug-like compounds. These four metabolites, namely, sesamin, sesaminol, sesamolin, and sesamolinol have the molar refractivity values 90, 92.02, 91.52, and 93.98, respectively; these compounds also present the scores of the synthetic accessibility (SA): 4.12, 4.31, 4.43, and 4.50, respectively. SA is one of the important parameters of synthesis during the process of drug designing (<xref ref-type="bibr" rid="B33">Ertl and Schuffenhauer, 2009</xref>). The predicted SA score of these screened compounds was &#x3c;10, which suggested that these compounds can be easily synthesized. Taken together, the drug-likeness analysis indicated that these sesame-derived natural metabolites possess favorable pharmacokinetic properties, and thus can be considered drug-like molecules.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>ADME properties of screened top four compounds from sesame (<italic>S. indicum</italic> L.).</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Drug-likeliness properties</th>
<th rowspan="2" align="center">MW (g/mol) (range &#x2264;500&#xa0;g)</th>
<th rowspan="2" align="center">Consensus log Po/w (range &#x2264;5)</th>
<th rowspan="2" align="center">No. of H bond acceptors (range &#x2264;10)</th>
<th rowspan="2" align="center">No. of H bond donors (range &#x2264;5)</th>
<th rowspan="2" align="center">Molar refractivity (range 40&#x2013;130)</th>
<th rowspan="2" align="center">Lipinski</th>
<th rowspan="2" align="center">Veber</th>
<th rowspan="2" align="center">Bioavailability score (range 0.4&#x2013;0.6)</th>
<th rowspan="2" align="center">Synthetic accessibility (range &#x3e;6)</th>
<th rowspan="2" align="center">TPSA (&#xc5;2) (range &#x3e;100)</th>
<th rowspan="2" align="center">No. of rotatable bonds (range 1&#x2013;10)</th>
<th rowspan="2" align="center">Solubility (mg/ml)</th>
</tr>
<tr>
<th align="left">Phytochemical</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Sesamin (CID_72307)</td>
<td align="center">354.35</td>
<td align="center">2.79</td>
<td align="center">6</td>
<td align="center">0</td>
<td align="center">90.00</td>
<td align="left">Yes</td>
<td align="left">Yes</td>
<td align="center">0.55</td>
<td align="center">4.12</td>
<td align="center">55.38</td>
<td align="center">2</td>
<td align="center">8.98e-03</td>
</tr>
<tr>
<td align="left">Sesaminol (CID_94672)</td>
<td align="center">370.35</td>
<td align="center">2.37</td>
<td align="center">7</td>
<td align="center">1</td>
<td align="center">92.02</td>
<td align="left">Yes</td>
<td align="left">Yes</td>
<td align="center">0.55</td>
<td align="center">4.31</td>
<td align="center">75.61</td>
<td align="center">2</td>
<td align="center">3.62e-02</td>
</tr>
<tr>
<td align="left">Sesamolin (CID_131801617)</td>
<td align="center">370.35</td>
<td align="center">2.74</td>
<td align="center">7</td>
<td align="center">3</td>
<td align="center">91.52</td>
<td align="left">Yes</td>
<td align="left">Yes</td>
<td align="center">0.55</td>
<td align="center">4.43</td>
<td align="center">64.61</td>
<td align="center">3</td>
<td align="center">1.75e-02</td>
</tr>
<tr>
<td align="left">Sesamolinol (CID_443019)</td>
<td align="center">372.37</td>
<td align="center">2.56</td>
<td align="center">7</td>
<td align="center">1</td>
<td align="center">93.98</td>
<td align="left">Yes</td>
<td align="left">Yes</td>
<td align="center">0.55</td>
<td align="center">4.50</td>
<td align="center">75.61</td>
<td align="center">4</td>
<td align="center">2.80e-02</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-3">
<title>Conformation of Stability of Docking Complexes for Natural Compounds and SARS-CoV-2&#x20;M<sup>pro</sup> by Molecular Dynamics Simulations</title>
<p>In order to determine the structural stability of docking complexes, MD simulations were run with the most stable docked models on 200&#xa0;ns. Based on docking scores, hydrogen bonds, and compound specificity, four docking complexes, namely, sesamin, sesaminol, sesamolin, and sesamolinol were subjected to MD simulations. High binding energy scores of docking complexes allowed for the estimation of the amino acid residue interactions over time. The RMSD, RMSF, SASA, and Rg plots were calculated to evaluate the stability of simulated systems.</p>
</sec>
<sec id="s3-4">
<title>Root-Mean-Square Deviation</title>
<p>The RMSD is a most commonly used quantitative method to evaluate the stability of the docking complexes and measures the conformational stability perturbations within the protein backbone during MD simulations on different nanosecond scales (<xref ref-type="bibr" rid="B91">Sargsyan et&#x20;al., 2017</xref>). In order to investigate the stability of the ligand molecules to the protein, all the ligand and backbone RMSDs were graphically measured. As evident from <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>, the protein backbone of M<sup>pro</sup> showed constant stability throughout the simulation with a range between 0.37 and 0.47&#xa0;nm. The average RMSD values for complexes with sesamin, sesaminol, sesamolin, and sesamolinol were &#x223c;0.37, &#x223c; 0.38, &#x223c; 0.31, and &#x223c;0.38&#xa0;nm, respectively. Likewise, the control (blue) element also showed the average value of RMSD to be around 0.47&#xa0;nm. The complex with sesaminol (yellow) and sesamolinol (cyan) displayed higher simulation trajectory after &#x223c;50&#xa0;ns than the complex with sesamin (red) and sesamolin (green). The compound sesamolin has shown two fluctuations throughout the simulations on 200&#xa0;ns time scale. The first stable conformation was noted between 25 and 100&#xa0;ns, and the second stable conformation was found between 110 and 200&#xa0;ns. The RMSD constant was at &#x223c;0.25, and a large fluctuation was observed between 10 and 25&#xa0;ns. However, there was no significant effect of this fluctuation was found on the protein structure. Sesamolinol showed slight changes in the starting period of simulation between 2 and 25&#xa0;ns. After 25&#xa0;ns, sesamolinol was found to be constant at &#x223c;0.35 throughout the simulations. It may be because of the binding region size and loop presence at the pocket site. All the four ligand molecules shared the almost similar trend of stability and RMSD values with small conformational changes. As depicted in <xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>, the calculated ligand RMSD plot is the conformation of the measured protein backbone; RMSD plot shows the stability of target compounds throughout the simulation with fluctuation in sesamolinol at starting point between 5 and 15&#xa0;ns on &#x223c;0.50&#xa0;nm. In the same plot, the sesamolin compound also showed the fluctuation between 160 and 170&#xa0;ns on &#x223c;0.25&#xa0;nm. Based on the minimal fluctuations and low difference in values depicted in the protein backbone and ligand RMSD plots, it can be predicted that protein&#x2013;ligand complexes were stable and comparable to solved structures. The docked pose of our ligands is fixed in the active region, same as the crystal structure ligand Z45617795, which is quite acceptable in protein&#x2013;ligand interaction (<xref ref-type="table" rid="T1">Table&#x20;1</xref>). The RMSDs of our ligands with heavy atoms are similar to crystal structure resolution which is higher than 1.65&#xa0;&#xc5; and is accurately ordered and exactly fitted in the electron density map. Therefore, RMSDs obtained from MD simulation also showed the structure stability during simulation (each ligand has remained constant and has a constant range of RMSDs). From these observations, we assume that our ligand RMSDs (0.25&#x2013;1&#xa0;nm) showed similar stability as crystal ligand pose has in resolutions.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>RMSD analysis. <bold>(A)</bold> Backbone RMSD plot of docking complexes; and <bold>(B)</bold> ligand RMSD plot of complexes [M<sup>pro</sup> &#x2013; sesamin complex (red), M<sup>pro</sup> &#x2013; sesamolin complex (green), M<sup>pro</sup> &#x2013; sesaminol complex (yellow), M<sup>pro</sup> &#x2013; sesamolinol complex (cyan), and control (blue)].</p>
</caption>
<graphic xlink:href="fchem-09-744376-g004.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Root-Mean-Square Fluctuation</title>
<p>In order to determine the individual residue flexibility of the system with the time, RMSF was calculated, in which high fluctuation score indicates more flexibility and unstable bonds, while a low score reflects well-structured regions in the protein&#x2013;ligand complexes (<xref ref-type="bibr" rid="B35">Gajula et&#x20;al., 2016</xref>). The RMSF of alpha-carbon atoms of all system was investigated and is given in <xref ref-type="fig" rid="F5">Figure&#x20;5</xref>. All the five systems (control, M<sup>pro</sup>&#x2013;sesamin, M<sup>pro</sup>&#x2013;sesaminol, M<sup>pro</sup>&#x2013;sesamolin, and M<sup>pro</sup>&#x2013;sesamolinol complexes) demonstrated almost a similar pattern of fluctuation across the whole structure during simulation. The average RMSF values of control, M<sup>pro</sup>&#x2013; sesamin, M<sup>pro</sup>&#x2013; sesaminol, M<sup>pro</sup>&#x2013; sesamolin, and M<sup>pro</sup>&#x2013; sesamolinol complexes were &#x223c;0.25, &#x223c;0.20, &#x223c;0.23, &#x223c;0.21, and &#x223c;0.35&#xa0;nm, respectively. These values revealed that all the subjected docking complexes exhibit relatively less conformation fluctuation than the control system. These less fluctuations of the docking complexes suggested that the residues distributed across the active site of M<sup>pro</sup> interact with sesamin, sesaminol, sesamolin, and sesamolinol in a significant manner.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Calculated RMSF plot of docking complexes[M<sup>pro</sup> &#x2013; sesamin complex (red), M<sup>pro</sup> &#x2013; sesamolin complex (green), M<sup>pro</sup> &#x2013; sesaminol complex (yellow), M<sup>pro</sup> &#x2013; sesamolinol complex (cyan), and control (blue)].</p>
</caption>
<graphic xlink:href="fchem-09-744376-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Hydrogen Bond Analysis</title>
<p>Hydrogen bonds play an essential role in establishing molecular interactions of biological systems. The molecular interaction between M<sup>pro</sup> and sesame-derived bioactive molecules was explored by the secondary structure changes, which is, in turn, regulated by a number of hydrogen bonds. For selected complexes (M<sup>pro</sup>&#x2013; sesamin, M<sup>pro</sup>&#x2013; sesaminol, M<sup>pro</sup>&#x2013; sesamolin, and M<sup>pro</sup>&#x2013; sesamolinol), a number of formed hydrogen bonds were calculated throughout the MD simulation on the scale of 200&#xa0;ns. The number of hydrogen bonds and hydrogen bond distribution is represented in <xref ref-type="fig" rid="F6">Figure&#x20;6</xref>. In complex with sesaminol (yellow) and sesamolinol (cyan), the numbers of hydrogen bonds were three, with few conformations showing up to 4 hydrogen bonds throughout the simulations. Sesamin (red) and sesamolin (green) have a constant range of hydrogen bonds between two and three in whole simulation. These results showed that the screened natural metabolites were able to maintain a strong interaction with a pocket site and suggested that all four docking complexes were stable throughout the simulation.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Hydrogen bond analysis of docking complexes [M<sup>pro</sup> &#x2013; sesamin complex (red), M<sup>pro</sup> &#x2013; sesamolin complex (green), M<sup>pro</sup> &#x2013; sesaminol complex (yellow), and M<sup>pro</sup> &#x2013; sesamolinol complex (cyan)].</p>
</caption>
<graphic xlink:href="fchem-09-744376-g006.tif"/>
</fig>
</sec>
<sec id="s3-7">
<title>Radius of Gyration, and Solvent Accessible Surface Area Analysis</title>
<p>MD trajectories corresponding to four complexes (M<sup>pro</sup>&#x2013; sesamin, M<sup>pro</sup>&#x2013; sesaminol, M<sup>pro</sup>&#x2013; sesamolin, and M<sup>pro</sup>&#x2013; sesamolinol) were further investigated with the aid of Rg and SASA analysis. Rg was calculated with a primary goal to determine the compactness of the system with the time. As depicted in <xref ref-type="fig" rid="F7">Figure&#x20;7A</xref>, the Rg values of all four systems with control were reported as 2.08&#x2013;2.15&#xa0;nm throughout the simulation. Rg value analysis affirms the stability of each system and suggested that the binding of screened natural phytochemicals does not induce structural changes during whole simulation. During simulation, SASA values were calculated to measure the receptor exposed to the solvents. It is well-documented that a higher SASA value reflects the expansion of protein volume during MD simulation (<xref ref-type="bibr" rid="B58">Kumar et&#x20;al., 2020</xref>). Always, a low fluctuation is expected during whole simulation. Interaction with ligand compounds may influence SASA and sometimes affect the protein structure in a significant manner. The calculated SASA values showed between 130 and 148&#xa0;nm<sup>2</sup>, reflecting that the binding of sesamin, sesaminol, sesamolin, and sesamolinol does not affect the folding of protein (<xref ref-type="fig" rid="F7">Figure&#x20;7B</xref>). The calculated SASA values for these ligand compounds are the consent of previous reports (<xref ref-type="bibr" rid="B58">Kumar et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B71">Mishra et&#x20;al., 2021</xref>) and suggested that all of the four complexes were stable after the binding of sesamin, sesaminol, sesamolin, and sesamolinol to the M<sup>pro</sup> active&#x20;site.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Rg and SASA analysis. <bold>(A)</bold> Predicted Rg plot of docking complexes; and <bold>(B)</bold> SASA plot of selected complexes [M<sup>pro</sup> &#x2013; sesamin complex (red), M<sup>pro</sup> &#x2013; sesamolin complex (green), M<sup>pro</sup> &#x2013; sesaminol complex (yellow), M<sup>pro</sup> &#x2013; sesamolinol complex (cyan), and control (blue)].</p>
</caption>
<graphic xlink:href="fchem-09-744376-g007.tif"/>
</fig>
</sec>
<sec id="s3-8">
<title>Estimation of Binding Free Energy</title>
<p>The average free binding energy of selected complexes (M<sup>pro</sup>&#x2013; sesamin, M<sup>pro</sup>&#x2013; sesaminol, M<sup>pro</sup>&#x2013; sesamolin, and M<sup>pro</sup>&#x2013; sesamolinol) was calculated by using a python script MmPbSaStat.py embedded in g_mmpbsa package. The molecular mechanic/Poisson&#x2013;Boltzmann surface area (MM/PBSA) is one of the popular and accurate methods to estimate the ligand binding affinities in the protein system. To calculate the binding free energy, we have utilized the steps previously described (<xref ref-type="bibr" rid="B35">Gajula et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B49">Jee et&#x20;al., 2017</xref>). The MM/PBSA-based binding energy score extracted after the systematical calculation is provided in <xref ref-type="table" rid="T3">Table&#x20;3</xref>. The cumulative sum of different energies such as van der Walls, electrostatic, polar solvation, and SASA is presented as the final binding energy. All types of the energy significantly contributed to the molecular interaction between the ligand compounds and M<sup>pro</sup>. The evaluated binding free energy of screened molecules exhibited as sesamin (&#x2212;145.511&#x20;&#xb1; 17.054&#xa0;kJ/mol), sesamolin (&#x2212;211.240&#x20;&#xb1; 14.034&#xa0;kJ/mol), sesaminol (&#x2212;149.078&#x20;&#xb1; 9.043&#xa0;kJ/mol) and sesamolinol (&#x2212;199.110&#x20;&#xb1; 15.881&#xa0;kJ/mol). The negative values of the binding energy reflect that the targeted compound favorably interact with the receptor protein. As compared with other screened compounds, the sesamolin (&#x2212;211.240&#x20;&#xb1; 14.034&#xa0;kJ/mol) showed the maximum negative binding energy. The MM/PBSA results clearly suggest that sesamolinol (&#x2212;199.110&#x20;&#xb1; 15.881&#xa0;kJ/mol) possessed the second least binding energy. These natural compounds with the maximum negative binding energy and better binding affinity could be utilized as potential inhibitors against the M<sup>pro</sup> of COVID-19.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Calculated total binding energy, van der Waals energy, electrostatic energy, polar solvation energy, and SASA energy of the docking complexes.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Complex</th>
<th align="center">Binding energy (kJ/mol)</th>
<th align="center">van der Waals energy (&#x2206;EvdW) (kJ/mol)</th>
<th align="center">Electrostatic energy (&#x2206;Elec), (kJ/mol)</th>
<th align="center">Polar solvation energy (&#x2206;G polar) (kJ/mol)</th>
<th align="center">SASA energy (kJ/mol)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Sesamin</td>
<td align="char" char="plusmn .">&#x2212;145.511&#x20;&#xb1; 17.054</td>
<td align="char" char="plusmn .">&#x2212;185.239&#x20;&#xb1; 12.497</td>
<td align="char" char="plusmn .">&#x2212;1.331&#x20;&#xb1; 2.720</td>
<td align="char" char="plusmn .">56.328&#x20;&#xb1; 10.084</td>
<td align="char" char="plusmn .">&#x2212;15.269&#x20;&#xb1; 0.859</td>
</tr>
<tr>
<td align="left">Sesamolin</td>
<td align="char" char="plusmn .">&#x2212;211.240&#x20;&#xb1; 14.034</td>
<td align="char" char="plusmn .">&#x2212;244.688&#x20;&#xb1; 13.232</td>
<td align="char" char="plusmn .">&#x2212;2.394&#x20;&#xb1; 2.452</td>
<td align="char" char="plusmn .">53.429&#x20;&#xb1; 6.865</td>
<td align="char" char="plusmn .">&#x2212;17.587&#x20;&#xb1; 0.839</td>
</tr>
<tr>
<td align="left">Sesaminol</td>
<td align="char" char="plusmn .">&#x2212;149.078&#x20;&#xb1; 9.043</td>
<td align="char" char="plusmn .">&#x2212;158.179&#x20;&#xb1; 8.593</td>
<td align="char" char="plusmn .">&#x2212;1.087&#x20;&#xb1; 1.785</td>
<td align="char" char="plusmn .">24.598&#x20;&#xb1; 4.487</td>
<td align="char" char="plusmn .">&#x2212;14.410&#x20;&#xb1; 0.870</td>
</tr>
<tr>
<td align="left">Sesamolinol</td>
<td align="char" char="plusmn .">&#x2212;199.110&#x20;&#xb1; 15.881</td>
<td align="char" char="plusmn .">&#x2212;233.811&#x20;&#xb1; 13.828</td>
<td align="char" char="plusmn .">2.162&#x20;&#xb1; 2.619</td>
<td align="char" char="plusmn .">51.381&#x20;&#xb1; 7.632</td>
<td align="char" char="plusmn .">&#x2212;18.842&#x20;&#xb1; 0.954</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>The inhibition of M<sup>pro</sup> protein represents a promising strategy for&#x20;controlling viral replication leading to discovery of potential drug candidates. The current extensive study concludes four phytochemicals, namely, sesamin, sesaminol, sesamolin, and sesamolinol as potential inhibitors against the M<sup>pro</sup> of SARS-CoV-2. The integrated molecular docking and MD simulation study revealed that these bioactive molecules form a very stable complex with M<sup>pro</sup> that shows excellent binding affinities higher than other sesame-derived molecules. Docking complexes of these natural metabolites with M<sup>pro</sup> showed a stable conformation on 200&#xa0;ns, which is further supported by the results of binding free&#x20;energy. Moreover, the proposed potential inhibitors also meet the criteria of drug likeness based on Lipinski&#x2019;s rule of five and ADME properties. The inhibitory effect of these sesame-derived natural compounds against the M<sup>pro</sup> of SARS-CoV-2 may also be further validated using a plethora of <italic>in&#x20;vitro</italic> and <italic>in vivo</italic> experiments. The current study suggested that the screened phytochemicals (sesamin, sesaminol, sesamolin, and sesamolinol) have shown enough potential to inhibit the M<sup>pro</sup> and may be utilized as effective drug candidates for the development of new treatment against COVID-19 infection.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="sec" rid="s10">Supplementary Material</xref>.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>AK and UA contributed to conception, design, and data acquisition. AK drafted the manuscript. DM contributed to data analysis. UA, RY, AR, and DK proofread the final manuscript. All authors gave final approval and agreed to be accountable for all aspects of the&#x20;work.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This research was funded by the Department of Biotechnology, Ministry of Science and Technology, government of India (grant number BT/Ag/Network/Sesame/2019-20).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>The authors are thankful to Gourav Choudhir<italic>,</italic> Indian Institute of Technology, Delhi, for his technical support in molecular dynamics simulations. The authors are also thankful to Indian Council of Agricultural Research, Ministry of Agriculture and Farmers&#x2019; Welfare, government of India, for use of Advanced Super Computing Hub for Omics Knowledge in Agriculture (ASHOKA) facility.</p>
</ack>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fchem.2021.744376/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fchem.2021.744376/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.DOCX" id="SM1" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aanouz</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Belhassan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>El-Khatabi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lakhlifi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>El-ldrissi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bouachrine</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Moroccan Medicinal Plants as Inhibitors against SARS-CoV-2 Main Protease: Computational Investigations</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>2971</fpage>&#x2013;<lpage>2979</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1758790</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdelli</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hassani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bekkel Brikci</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ghalem</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>In Silico study the Inhibition of Angiotensin Converting Enzyme 2 Receptor of COVID-19 by Ammoides Verticillata Components Harvested from Western Algeria</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>1</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1763199</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abraham</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Gready</surname>
<given-names>J.&#x20;E.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Optimization of Parameters for Molecular Dynamics Simulation Using Smooth Particle-Mesh Ewald in GROMACS 4.5</article-title>. <source>J.&#x20;Comput. Chem.</source> <volume>32</volume>, <fpage>2031</fpage>&#x2013;<lpage>2040</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21773</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abraham</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Murtola</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>P&#xe1;ll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>GROMACS: High Performance Molecular Simulations through Multi-Level Parallelism from Laptops to Supercomputers</article-title>. <source>SoftwareX</source> <volume>1&#x2013;2</volume>, <fpage>19</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.softx.2015.06.001</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahuja</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tyagi</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Tyagi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sharifi-Rad</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Potential of Pueraria Tuberosa (Willd.) DC. To rescue Cognitive Decline Associated with BACE1 Protein of Alzheimer&#x27;s Disease on Drosophila Model: An Integrated Molecular Modeling and <italic>In Vivo</italic> Approach</article-title>. <source>Int. J.&#x20;Biol. Macromolecules</source> <volume>179</volume>, <fpage>586</fpage>&#x2013;<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.03.032</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aldeghi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bodkin</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Knapp</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Biggin</surname>
<given-names>P. C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Statistical Analysis on the Performance of Molecular Mechanics Poisson-Boltzmann Surface Area versus Absolute Binding Free Energy Calculations: Bromodomains as a Case Study</article-title>. <source>J.&#x20;Chem. Inf. Model.</source> <volume>57</volume>, <fpage>2203</fpage>&#x2013;<lpage>2221</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.7b00347</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allam</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Amen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ashour</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Assaf</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Abdel-Rahman</surname>
<given-names>I. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>In Silico study of Natural Compounds from Sesame against COVID-19 by Targeting Mpro, PLpro and RdRp</article-title>. <source>RSC Adv.</source> <volume>11</volume>, <fpage>22398</fpage>&#x2013;<lpage>22408</lpage>. <pub-id pub-id-type="doi">10.1039/D1RA03937G</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arden</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Nissen</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Sloots</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Mackay</surname>
<given-names>I. M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>New Human Coronavirus, HCoV-NL63, Associated with Severe Lower Respiratory Tract Disease in Australia</article-title>. <source>J.&#x20;Med. Virol.</source> <volume>75</volume>, <fpage>455</fpage>&#x2013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.20288</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Backer</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Klinkenberg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wallinga</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Incubation Period of 2019 Novel Coronavirus (2019-nCoV) Infections Among Travellers from Wuhan, China, 20-28 January 2020</article-title>. <source>Eurosurveillance</source> <volume>25</volume>, <fpage>2000062</fpage>. <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.5.2000062</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bello</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mart&#xed;nez-Mu&#xf1;oz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Balbuena-Rebolledo</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Identification of Saquinavir as a Potent Inhibitor of Dimeric SARS-CoV2 Main Protease through MM/GBSA</article-title>. <source>J.&#x20;Mol. Model.</source> <volume>26</volume>, <fpage>340</fpage>. <pub-id pub-id-type="doi">10.1007/s00894-020-04600-4</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berman</surname>
<given-names>H. M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>The Protein Data Bank</article-title>. <source>Nucleic Acids Res.</source> <volume>28</volume>, <fpage>235</fpage>&#x2013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhat</surname>
<given-names>K. V.</given-names>
</name>
<name>
<surname>Kumari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pathak</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rai</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Value Addition in Sesame: A Perspective on Bioactive Components for Enhancing Utility and Profitability</article-title>. <source>Phcog Rev.</source> <volume>8</volume>, <fpage>147</fpage>. <pub-id pub-id-type="doi">10.4103/0973-7847.134249</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burley</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Bhikadiya</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Di Costanzo</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>RCSB Protein Data Bank: Biological Macromolecular Structures Enabling Research and Education in Fundamental Biology, Biomedicine, Biotechnology and Energy</article-title>. <source>Nucleic Acids Res.</source> <volume>47</volume>, <fpage>D464</fpage>&#x2013;<lpage>D474</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1004</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>C.-k.</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>S.-C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.-S.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>M.-H.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Recent Insights into the Development of Therapeutics against Coronavirus Diseases by Targeting N Protein</article-title>. <source>Drug Discov. Today</source> <volume>21</volume>, <fpage>562</fpage>&#x2013;<lpage>572</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2015.11.015</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>Y.-A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.-F.</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H.-C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking</article-title>. <source>Preprints</source>, <fpage>2020020242</fpage>. <pub-id pub-id-type="doi">10.20944/preprints202002.0242.v1</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>Clinical Characteristics of 113 Deceased Patients with Coronavirus Disease 2019: Retrospective Study</article-title>. <source>BMJ</source> <volume>368</volume>, <fpage>m1091</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m1091</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020b</year>). <article-title>Emerging Coronaviruses: Genome Structure, Replication, and Pathogenesis</article-title>. <source>J.&#x20;Med. Virol.</source> <volume>92</volume>, <fpage>418</fpage>&#x2013;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25681</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>V. C. C.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>S. K. P.</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>P. C. Y.</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>K. Y.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>20</volume>, <fpage>660</fpage>&#x2013;<lpage>694</lpage>. <pub-id pub-id-type="doi">10.1128/cmr.00023-07</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chikhale</surname>
<given-names>R. V.</given-names>
</name>
<name>
<surname>Gurav</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Shakya</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>Sars-cov-2 Host Entry and Replication Inhibitors from Indian Ginseng: an In-Silico Approach</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>4510</fpage>&#x2013;<lpage>4521</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1778539</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chikhale</surname>
<given-names>R. V.</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Shakya</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gurav</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>In-silico Investigation of Phytochemicals from <italic>Asparagus racemosus</italic> as Plausible Antiviral Agent in COVID-19</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>5033</fpage>&#x2013;<lpage>5047</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1784289</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>B.-H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.-D.</given-names>
</name>
<name>
<surname>Jeoung</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Choe</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Angiogenic Activity of Sesamin through the Activation of Multiple Signal Pathways</article-title>. <source>Biochem. Biophysical Res. Commun.</source> <volume>391</volume>, <fpage>254</fpage>&#x2013;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2009.11.045</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Contini</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Virtual Screening of an FDA Approved Drugs Database on Two COVID-19 Coronavirus Proteins</article-title>. <source>Life Sci.</source> <volume>251</volume>, <fpage>117627</fpage>. <pub-id pub-id-type="doi">10.26434/chemrxiv.11847381.v1</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Michielin</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Zoete</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>42717</fpage>. <pub-id pub-id-type="doi">10.1038/srep42717</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalibalta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Majdalawieh</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Manjikian</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Health Benefits of Sesamin on Cardiovascular Disease and its Associated Risk Factors</article-title>. <source>Saudi Pharm. J.</source> <volume>28</volume>, <fpage>1276</fpage>&#x2013;<lpage>1289</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsps.2020.08.018</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dar</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Arumugam</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Lignans of Sesame: Purification Methods, Biological Activities and Biosynthesis - A Review</article-title>. <source>Bioorg. Chem.</source> <volume>50</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2013.06.009</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sarmah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lyndem</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singha Roy</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>An Investigation into the Identification of Potential Inhibitors of SARS-CoV-2 Main Protease Using Molecular Docking Study</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>3347</fpage>&#x2013;<lpage>3357</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1763201</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Wit</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>van Doremalen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Falzarano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Munster</surname>
<given-names>V. J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>SARS and MERS: Recent Insights into Emerging Coronaviruses</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>14</volume>, <fpage>523</fpage>&#x2013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>DeLano</surname>
<given-names>W. L.</given-names>
</name>
</person-group> (<year>2002</year>). <source>The PyMOL Molecular Graphics System</source>. <publisher-loc>San Carlos, CA</publisher-loc>: <publisher-name>DeLano Scientific</publisher-name>. </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dravie</surname>
<given-names>E. E.</given-names>
</name>
<name>
<surname>Kortei</surname>
<given-names>N. K.</given-names>
</name>
<name>
<surname>Essuman</surname>
<given-names>E. K.</given-names>
</name>
<name>
<surname>Tettey</surname>
<given-names>C. O.</given-names>
</name>
<name>
<surname>Boakye</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Hunkpe</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Antioxidant, Phytochemical and Physicochemical Properties of Sesame Seed (Sesamum indicum L)</article-title>. <source>Scientific Afr.</source> <volume>8</volume>, <fpage>e00349</fpage>. <pub-id pub-id-type="doi">10.1016/j.sciaf.2020.e00349</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elfiky</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Azzam</surname>
<given-names>E. B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Novel Guanosine Derivatives against MERS CoV Polymerase: An In Silico Perspective</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>2923</fpage>&#x2013;<lpage>2931</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1758789</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elfiky</surname>
<given-names>A. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) Targeting: An <italic>In Silico</italic> Perspective</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>3204</fpage>&#x2013;<lpage>3212</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761882</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enayatkhani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hasaniazad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Faezi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gouklani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Davoodian</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ahmadi</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Reverse Vaccinology Approach to Design a Novel Multi-Epitope Vaccine Candidate against COVID-19: an In Silico Study</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>2857</fpage>&#x2013;<lpage>2872</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1756411</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ertl</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schuffenhauer</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Estimation of Synthetic Accessibility Score of Drug-like Molecules Based on Molecular Complexity and Fragment Contributions</article-title>. <source>J.&#x20;Cheminform</source> <volume>1</volume>, <fpage>8</fpage>. <pub-id pub-id-type="doi">10.1186/1758-2946-1-8</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fanhchaksai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kodchakorn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pothacharoen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kongtawelert</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Effect of Sesamin against Cytokine Production from Influenza Type A H1N1-Induced Peripheral Blood Mononuclear Cells: Computational and Experimental Studies <italic>In Vitro</italic>
</article-title>. <source>Cell. Dev. Biol.</source> <volume>52</volume>, <fpage>107</fpage>&#x2013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1007/s11626-015-9950-7</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gajula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ijaq</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Protocol for Molecular Dynamics Simulations of Proteins</article-title>. <source>Bio-protocol</source> <volume>85</volume>, <fpage>159</fpage>&#x2013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.21769/bioprotoc.2051</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Paz</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Lossada</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Moncayo</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Paz</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Vera-Villalobos</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <source>Theoretical Molecular Docking Study of the Structural Disruption of the Viral 3CL-Protease of COVID19 Induced by Binding of Capsaicin, Piperine and Curcumin Part 1: A Comparative Study with Chloroquine and Hydrochloroquine Two Antimalaric Drugs</source>. <publisher-name>Research Square</publisher-name>. <pub-id pub-id-type="doi">10.21203/rs.3.rs-21206/v1</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Bouhaddou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Obernier</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>O&#x2019;Meara</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing</article-title>. <source>Nature</source> <volume>583</volume>, <fpage>459</fpage>&#x2013;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1101/2020.03.22.002386</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grougnet</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Magiatis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Laborie</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lazarou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Papadopoulos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Skaltsounis</surname>
<given-names>A.-L.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Sesamolinol Glucoside, Disaminyl Ether, and Other Lignans from Sesame Seeds</article-title>. <source>J.&#x20;Agric. Food Chem.</source> <volume>60</volume>, <fpage>108</fpage>&#x2013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1021/jf2040687</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guex</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Peitsch</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>SWISS-MODEL and the Swiss-Pdb Viewer: An Environment for Comparative Protein Modeling</article-title>. <source>Electrophoresis</source> <volume>18</volume>, <fpage>2714</fpage>&#x2013;<lpage>2723</lpage>. <pub-id pub-id-type="doi">10.1002/elps.1150181505</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Gunda</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>P</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kishor</surname>
<given-names>P. B. K.</given-names>
</name>
<name>
<surname>S</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2021</year>). <source>Natural Xanthone Compounds as Promising Drug Candidates against COVID-19 - an Integrated Molecular Docking and Dynamics Simulation Study</source>. <publisher-name>Research Square</publisher-name>. <pub-id pub-id-type="doi">10.21203/rs.3.rs-102884/v2</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Madhavan</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Sehgal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mahajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sehrawat</surname>
<given-names>T. S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Extrapulmonary Manifestations of COVID-19</article-title>. <source>Nat. Med.</source> <volume>26</volume>, <fpage>1017</fpage>&#x2013;<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0968-3</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Paray</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Qadir</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Attar</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>F. M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Review on the Cleavage Priming of the Spike Protein on Coronavirus by Angiotensin-Converting Enzyme-2 and Furin</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>3025</fpage>&#x2013;<lpage>3033</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1754293</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helmy</surname>
<given-names>Y. A.</given-names>
</name>
<name>
<surname>Fawzy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Elaswad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sobieh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kenney</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Shehata</surname>
<given-names>A. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control</article-title>. <source>Jcm</source> <volume>9</volume>, <fpage>1225</fpage>. <pub-id pub-id-type="doi">10.3390/jcm9041225</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hess</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bekker</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Berendsen</surname>
<given-names>H. J.&#x20;C.</given-names>
</name>
<name>
<surname>Fraaije</surname>
<given-names>J.&#x20;G. E. M.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>LINCS: A Linear Constraint Solver for Molecular Simulations</article-title>. <source>J.&#x20;Comput. Chem.</source> <volume>18</volume>, <fpage>1463</fpage>&#x2013;<lpage>1472</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1096-987x(199709)18:12&#x3c;1463:aid-jcc4&#x3e;3.0.co;2-h</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hess</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation</article-title>. <source>J.&#x20;Chem. Theor. Comput.</source> <volume>4</volume>, <fpage>116</fpage>&#x2013;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1021/ct700200b</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hulswit</surname>
<given-names>R. J.&#x20;G.</given-names>
</name>
<name>
<surname>de Haan</surname>
<given-names>C. A. M.</given-names>
</name>
<name>
<surname>Bosch</surname>
<given-names>B.-J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Coronavirus Spike Protein and Tropism Changes</article-title>. <source>Adv. Virus. Res.</source> <volume>96</volume>, <fpage>29</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/bs.aivir.2016.08.004</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Islam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Parves</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Mamun</surname>
<given-names>A. A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Molecular Modeling Approach to Identify Effective Antiviral Phytochemicals against the Main Protease of SARS-CoV-2</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>3213</fpage>&#x2013;<lpage>3224</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761883</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jamwal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gautam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Elsworth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chawla</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>An Updated Insight into the Molecular Pathogenesis, Secondary Complications and Potential Therapeutics of COVID-19 Pandemic</article-title>. <source>Life Sci.</source> <volume>257</volume>, <fpage>118105</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2020.118105</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jee</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Ursolic Acid and Carvacrol May Be Potential Inhibitors of Dormancy Protein Small Heat Shock protein16.3 of <italic>Mycobacterium tuberculosis</italic>
</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>36</volume>, <fpage>3434</fpage>&#x2013;<lpage>3443</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2017.1389305</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Structural Basis for the Inhibition of SARS-CoV-2 Main Protease by Antineoplastic Drug Carmofur</article-title>. <source>Nat. Struct. Mol. Biol.</source> <volume>27</volume>, <fpage>529</fpage>&#x2013;<lpage>532</lpage>. <pub-id pub-id-type="doi">10.1038/s41594-020-0440-6</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joshi</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Jagdale</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Bansode</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Shankar</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Tellis</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Pandya</surname>
<given-names>V. K.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Discovery of Potential Multi-Target-Directed Ligands by Targeting Host-specific SARS-CoV-2 Structurally Conserved Main Protease</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>3099</fpage>&#x2013;<lpage>3114</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1760137</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaji</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matsui-Yuasa</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Omura</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kiyomoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kojima-Yuasa</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Sesaminol Prevents Parkinson&#x27;s Disease by Activating the Nrf2-ARE Signaling Pathway</article-title>. <source>Heliyon</source> <volume>6</volume>, <fpage>e05342</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2020.e05342</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kappo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Oyinloye</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ajiboye</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ojo</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Nwozo</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Cardioprotective and Antioxidant Influence of Aqueous Extracts from Sesamum indicum Seeds on Oxidative Stress Induced by Cadmium in Wistar Rats</article-title>. <source>Phcog Mag.</source> <volume>12</volume>, <fpage>170</fpage>. <pub-id pub-id-type="doi">10.4103/0973-1296.182155</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Zia</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ashraf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ul-Haq</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 via Integrated Computational Approach</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>2607</fpage>&#x2013;<lpage>2616</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1751298</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gindulyte</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>PubChem in 2021: New Data Content and Improved Web Interfaces</article-title>. <source>Nucleic Acids Res.</source> <volume>49</volume>, <fpage>D1388</fpage>&#x2013;<lpage>D1395</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa971</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kodchakorn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Poovorawan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Suwannakarn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kongtawelert</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Molecular Modelling Investigation for Drugs and Nutraceuticals Against Protease of SARS-CoV-2</article-title>. <source>J.&#x20;Mol. Graphics Model.</source> <volume>101</volume>, <fpage>107717</fpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2020.107717</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krupanidhi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Abraham Peele</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Venkateswarulu</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Ayyagari</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Nazneen Bobby</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>John Babu</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Screening of Phytochemical Compounds of Tinospora Cordifolia for Their Inhibitory Activity on SARS-CoV-2: an In Silico Study</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>5799</fpage>&#x2013;<lpage>5803</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1787226</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Choudhir</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tyagi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bhushan</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Identification of Phytochemical Inhibitors against Main Protease of COVID-19 Using Molecular Modeling Approaches</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>3760</fpage>&#x2013;<lpage>3770</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1772112</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Gajula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Uttarakhand Medicinal Plants Database (UMPDB): A Platform for Exploring Genomic, Chemical, and Traditional Knowledge</article-title>. <source>Data</source> <volume>3</volume>, <fpage>7</fpage>. <pub-id pub-id-type="doi">10.3390/data3010007</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lynn</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>g_mmpbsa-A GROMACS Tool for High-Throughput MM-PBSA Calculations</article-title>. <source>J.&#x20;Chem. Inf. Model.</source> <volume>54</volume>, <fpage>1951</fpage>&#x2013;<lpage>1962</lpage>. <pub-id pub-id-type="doi">10.1021/ci500020m</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kutzner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>P&#xe1;ll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fechner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Esztermann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Groot</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Grubm&#xfc;ller</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>More Bang for Your Buck: Improved Use of GPU Nodes for GROMACS 2018</article-title>. <source>J.&#x20;Comput. Chem.</source> <volume>40</volume>, <fpage>2418</fpage>&#x2013;<lpage>2431</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.26011</pub-id> </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Allen Chan</surname>
<given-names>K. C.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>E. K. O.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>R. W. K.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Effects of Early Corticosteroid Treatment on Plasma SARS-Associated Coronavirus RNA Concentrations in Adult Patients</article-title>. <source>J.&#x20;Clin. Virol.</source> <volume>31</volume>, <fpage>304</fpage>&#x2013;<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2004.07.006</pub-id> </citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipinski</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dominy</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Feeney</surname>
<given-names>P. J.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>46</volume>, <fpage>3</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/s0169-409x(00)00129-0</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipinski</surname>
<given-names>C. A.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Lead- and Drug-like Compounds: the Rule-Of-Five Revolution</article-title>. <source>Drug Discov. Today Tech.</source> <volume>1</volume>, <fpage>337</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.007</pub-id> </citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.-h.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z.-h.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.-s.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Potential Molecular Targets of Nonstructural Proteins for the Development of Antiviral Drugs against SARS-CoV-2 Infection</article-title>. <source>Biomed. Pharmacother.</source> <volume>133</volume>, <fpage>111035</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2020.111035</pub-id> </citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackenzie</surname>
<given-names>J.&#x20;S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>COVID-19: A Novel Zoonotic Disease Caused by a Coronavirus from China: what We Know and what We Don&#x2019;t</article-title>. <source>Microbiol. Aust.</source> <volume>41</volume>, <fpage>45</fpage>. <pub-id pub-id-type="doi">10.1071/ma20013</pub-id> </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahendra Kumar</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Bioactive Lignans from Sesame (<italic>Sesamum indicum</italic> L.): Evaluation of Their Antioxidant and Antibacterial Effects for Food Applications</article-title>. <source>J.&#x20;Food Sci. Technol.</source> <volume>52</volume>, <fpage>2934</fpage>&#x2013;<lpage>2941</lpage>. <pub-id pub-id-type="doi">10.1007/s13197-014-1334-6</pub-id> </citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Majdalawieh</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Massri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nasrallah</surname>
<given-names>G. K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>A Comprehensive Review on the AnticancerProperties and Mechanisms of Action of Sesamin, a Lignan in Sesame Seeds (<italic>Sesamum indicum</italic>)</article-title>. <source>Eur. J.&#x20;Pharmacol.</source> <volume>815</volume>, <fpage>512</fpage>&#x2013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2017.10.020</pub-id> </citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matveeva</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Khafizova</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sokornova</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>In Search of Herbal Anti-SARS-cov2 Compounds</article-title>. <source>Front. Plant Sci.</source> <volume>11</volume>, <fpage>589998</fpage>. <pub-id pub-id-type="doi">10.3389/fpls.2020.589998</pub-id> </citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maurya</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Evaluation of Traditional Ayurvedic Kadha for Prevention and Management of the Novel Coronavirus (SARS-CoV-2) Using <italic>In Silico</italic> Approach</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>30</volume>, <fpage>1</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1852119</pub-id> </citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michailidis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Angelis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aligiannis</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mitakou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Skaltsounis</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Recovery of Sesamin, Sesamolin, and Minor Lignans from Sesame Oil Using Solid Support-free Liquid-Liquid Extraction and Chromatography Techniques and Evaluation of Their Enzymatic Inhibition Properties</article-title>. <source>Front. Pharmacol.</source> <volume>10</volume>, <fpage>723</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.00723</pub-id> </citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mishra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pathak</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease: An In-Silico Study</article-title>. <source>Asian Pac. J.&#x20;Trop. Biomed.</source> <volume>11</volume>, <fpage>155</fpage>&#x2013;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.4103/2221-1691.310202</pub-id> </citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitra</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mahakur</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kamboj</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Molecular Docking and Simulation Studies of Natural Compounds of <italic>Vitex negundo</italic> L. Against Papain-Like Protease (PLpro) of SARS CoV-2 (Coronavirus) to Conquer the Pandemic Situation in the World</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>18</volume>, <fpage>1</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2021.1873185</pub-id> </citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyahara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hibasami</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Katsuzaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Osawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ina</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>Sesaminol from Sesame Seed Induces Apoptosis in Human Lymphoid Leukemia Molt 4B&#x20;Cells</article-title>. <source>Int. J.&#x20;Mol. Med.</source> <volume>7</volume>, <fpage>485</fpage>&#x2013;<lpage>488</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.7.5.485</pub-id> </citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Huey</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lindstrom</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sanner</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Belew</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Goodsell</surname>
<given-names>D. S.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility</article-title>. <source>J.&#x20;Comput. Chem.</source> <volume>30</volume>, <fpage>2785</fpage>&#x2013;<lpage>2791</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id> </citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muhammad</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Muangchoo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Muhammad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ajingi</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Muhammad</surname>
<given-names>I. Y.</given-names>
</name>
<name>
<surname>Umar</surname>
<given-names>I. D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Computational Study to Identify Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro) from Eucalyptus Active Compounds</article-title>. <source>Computation</source> <volume>8</volume>, <fpage>79</fpage>. <pub-id pub-id-type="doi">10.3390/computation8030079</pub-id> </citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagendra Prasad</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Sanjay</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>A Review on Nutritional and Nutraceutical Properties of Sesame</article-title>. <source>J.&#x20;Nutr. Food Sci.</source> <volume>02</volume>, <fpage>2</fpage>. <pub-id pub-id-type="doi">10.4172/2155-9600.1000127</pub-id> </citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Boyle</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Banck</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Morley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vandermeersch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hutchison</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Open Babel: An Open Chemical Toolbox</article-title>. <source>J.&#x20;Cheminform</source> <volume>3</volume>, <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id> </citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ojha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Choe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Farzan</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hydroxychloroquine-mediated Inhibition of SARS-CoV-2 Entry is Attenuated by TMPRSS2</article-title>. <source>PLOS Pathog.</source> <volume>17</volume>, <fpage>e1009212</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1009212</pub-id> </citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandey</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>An In-Silico Evaluation of Dietary Components for Structural Inhibition of SARS-Cov-2 Main Protease</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>0</volume>, <fpage>1</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1809522</pub-id> </citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pant</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ravichandiran</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Murty</surname>
<given-names>U. S. N.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>H. K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Peptide-like and Small-Molecule Inhibitors against Covid-19</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>2904</fpage>&#x2013;<lpage>2913</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1757510</pub-id> </citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>J.-A.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>H. J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Chalcones Isolated fromAngelica Keiskeiinhibit Cysteine Proteases of SARS-CoV</article-title>. <source>J.&#x20;Enzyme Inhib. Med. Chem.</source> <volume>31</volume>, <fpage>23</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.3109/14756366.2014.1003215</pub-id> </citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>S.-N.</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.-S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Antioxidant Components as Potential Neuroprotective Agents in Sesame (Sesamum indicumL.)</article-title>. <source>Food Rev. Int.</source> <volume>26</volume>, <fpage>103</fpage>&#x2013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1080/87559120903564464</pub-id> </citation>
</ref>
<ref id="B83">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Pathak</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bhaduri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rai</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2019</year>). &#x201c;<article-title>Sesame: Bioactive Compounds and Health Benefits</article-title>,&#x201d; in <source>Bioactive Molecules in Food</source> (<publisher-loc>Switzerland</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>), <fpage>181</fpage>&#x2013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-78030-6_59</pub-id> </citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pathak</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Choudhir</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Rifampicin and Letermovir as Potential Repurposed Drug Candidate for COVID-19 Treatment: Insights from an In-Silico Study</article-title>. <source>Pharmacol. Rep.</source> <volume>73</volume>, <fpage>926</fpage>&#x2013;<lpage>938</lpage>. <pub-id pub-id-type="doi">10.1007/s43440-021-00228-0</pub-id> </citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasanth</surname>
<given-names>D. S. N. B. K.</given-names>
</name>
<name>
<surname>Murahari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chandramohan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bhavya</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lakshmana Rao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Panda</surname>
<given-names>S. P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>In-silico Strategies of Some Selected Phytoconstituents from Melissa Officinalis as SARS CoV-2 Main Protease and Spike Protein (COVID-19) Inhibitors</article-title>. <source>Mol. Simulation</source> <volume>47</volume>, <fpage>457</fpage>&#x2013;<lpage>470</lpage>. <pub-id pub-id-type="doi">10.1080/08927022.2021.1880576</pub-id> </citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raj</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.&#x20;G.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ham</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Assessment of Antiviral Potencies of Cannabinoids against SARS-CoV-2 Using Computational and <italic>In Vitro</italic> Approaches</article-title>. <source>Int. J.&#x20;Biol. Macromolecules</source> <volume>168</volume>, <fpage>474</fpage>&#x2013;<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.12.020</pub-id> </citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romeo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mesiti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lupia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alcaro</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets</article-title>. <source>Molecules</source> <volume>26</volume>, <fpage>632</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26030632</pub-id> </citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schunk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sothmann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bretzel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Froeschl</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wallrauch</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>382</volume>, <fpage>970</fpage>&#x2013;<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2001468</pub-id> </citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rout</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Swain</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Tripathy</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>In Silico investigation of Spice Molecules as Potent Inhibitor of SARS-CoV-2</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>17</volume>, <fpage>1</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1819879</pub-id> </citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russell</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Golding</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Golding</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hellewell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Reconstructing the Early Global Dynamics of Under-ascertained COVID-19 Cases and Infections</article-title>. <source>BMC Med.</source> <volume>18</volume>, <fpage>332</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-020-01790-9</pub-id> </citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sargsyan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Grauffel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>How Molecular Size Impacts RMSD Applications in Molecular Dynamics Simulations</article-title>. <source>J.&#x20;Chem. Theor. Comput.</source> <volume>13</volume>, <fpage>1518</fpage>&#x2013;<lpage>1524</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jctc.7b00028</pub-id> </citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sch&#xfc;ttelkopf</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>van Aalten</surname>
<given-names>D. M. F.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>PRODRG: a Tool for High-Throughput Crystallography of Protein-Ligand Complexes</article-title>. <source>Acta Crystallogr. D Biol. Cryst.</source> <volume>60</volume>, <fpage>1355</fpage>&#x2013;<lpage>1363</lpage>. <pub-id pub-id-type="doi">10.1107/s0907444904011679</pub-id> </citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shamsi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohammad</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Anwar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Husain</surname>
<given-names>F. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Potential Drug Targets of SARS-CoV-2: From Genomics to Therapeutics</article-title>. <source>Int. J.&#x20;Biol. Macromolecules</source> <volume>177</volume>, <fpage>1</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.02.071</pub-id> </citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Host Susceptibility to Severe COVID-19 and Establishment of a Host Risk Score: Findings of 487 Cases Outside Wuhan</article-title>. <source>Crit. Care</source> <volume>24</volume>, <fpage>108</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-2833-7</pub-id> </citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Choudhir</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>P</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Unraveling the Potential Role of Bioactive Molecules Produced by <italic>Trichoderma</italic> spp. As Inhibitors of Tomatinase Enzyme Having an Important Role in Wilting Disease: An <italic>In-Silico</italic> Approach</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>15</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2021.1898476</pub-id> </citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinha</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Shakya</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gurav</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>R. S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>An In-Silico Evaluation of Different Saikosaponins for Their Potency Against SARS-CoV-2 Using NSP15 and Fusion Spike Glycoprotein as Targets</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>3244</fpage>&#x2013;<lpage>3255</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1762741</pub-id> </citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>A. C. K.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses</article-title>. <source>Trends Microbiol.</source> <volume>24</volume>, <fpage>490</fpage>&#x2013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/j.tim.2016.03.003</pub-id> </citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sultana</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Crisafulli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gabbay</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lynn</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shakir</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trifir&#xf2;</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Challenges for Drug Repurposing in the COVID-19 Pandemic Era</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>588654</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.588654</pub-id> </citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suravajhala</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Parashar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nagaraj</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Padmanaban</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kavi Kishor</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Comparative Docking Studies on Curcumin with COVID-19 Proteins</article-title>. <source>Netw. Model. Anal. Health Inform. Bioinform</source> <volume>10</volume>, <fpage>44</fpage>. <pub-id pub-id-type="doi">10.20944/preprints202005.0439.v1</pub-id> </citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Prevalence and Correlates of PTSD and Depressive Symptoms One Month after the Outbreak of the COVID-19 Epidemic in a Sample of home-quarantined Chinese university Students</article-title>. <source>J.&#x20;Affective Disord.</source> <volume>274</volume>, <fpage>1</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2020.05.009</pub-id> </citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tock</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Combrinck</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sandasi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kamatou</surname>
<given-names>G. P. P.</given-names>
</name>
<name>
<surname>Viljoen</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Exploring the Phytochemical Variation of Non-volatile Metabolites within Three South African Salvia Species Using UPLC-MS Fingerprinting and Chemometric Analysis</article-title>. <source>Fitoterapia</source> <volume>152</volume>, <fpage>104940</fpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2021.104940</pub-id> </citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tripathi</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Ethayathulla</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Identification of Bioactive Molecule from Withania Somnifera (Ashwagandha) as SARS-CoV-2 Main Protease Inhibitor</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>5668</fpage>&#x2013;<lpage>5681</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1790425</pub-id> </citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ullrich</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nitsche</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The SARS-CoV-2 Main Protease as Drug Target</article-title>. <source>Bioorg. Med. Chem. Lett.</source> <volume>30</volume>, <fpage>127377</fpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127377</pub-id> </citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uncu</surname>
<given-names>A. &#xd6;.</given-names>
</name>
<name>
<surname>Gultekin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Allmer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Frary</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Doganlar</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Genomic Simple Sequence Repeat Markers Reveal Patterns of Genetic Relatedness and Diversity in Sesame</article-title>. <source>Plant Genome</source> <volume>8</volume>, <fpage>0087</fpage>. <pub-id pub-id-type="doi">10.3835/plantgenome2014.11.0087</pub-id> </citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varadharajan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Arumugam</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Shanmugam</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Isatin-based Virtual High Throughput Screening, Molecular Docking, DFT, QM/MM, MD and MM-PBSA Study of Novel Inhibitors of SARS-CoV-2 Main Protease</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>25</volume>, <fpage>1</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2021.1904003</pub-id> </citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veber</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H.-Y.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Kopple</surname>
<given-names>K. D.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Molecular Properties that Influence the Oral Bioavailability of Drug Candidates</article-title>. <source>J.&#x20;Med. Chem.</source> <volume>45</volume>, <fpage>2615</fpage>&#x2013;<lpage>2623</lpage>. <pub-id pub-id-type="doi">10.1021/jm020017n</pub-id> </citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verdoni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mazza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gervasoni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ruggeri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ciuffreda</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>An Outbreak of Severe Kawasaki-like Disease at the Italian Epicentre of the SARS-CoV-2 Epidemic: An Observational Cohort Study</article-title>. <source>The Lancet</source> <volume>395</volume>, <fpage>1771</fpage>&#x2013;<lpage>1778</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)31103-x</pub-id> </citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wadood</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shams</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>In-silico Drug Design: An Approach Which Revolutionarised the Drug Discovery Process</article-title>. <source>OA Drug Des. Deliv.</source> <volume>1</volume>, <fpage>3</fpage>. <pub-id pub-id-type="doi">10.13172/2054-4057-1-1-1119</pub-id> </citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahedi</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Abbasi</surname>
<given-names>S. W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Stilbene-based Natural Compounds as Promising Drug Candidates against COVID-19</article-title>. <source>J.&#x20;Biomol. Struct. Dyn.</source> <volume>39</volume>, <fpage>3225</fpage>&#x2013;<lpage>3234</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1762743</pub-id> </citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2020a</year>). <article-title>Review of the 2019 Novel Coronavirus (SARS-CoV-2) Based on Current Evidence</article-title>. <source>Int. J.&#x20;Antimicrob. Agents</source> <volume>55</volume>, <fpage>105948</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105948</pub-id> </citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>Detection of SARS-CoV-2 in Different Types of Clinical Specimens</article-title>. <source>JAMA</source> <volume>323</volume>, <fpage>1843</fpage>&#x2013;<lpage>1844</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.3786</pub-id> </citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iizumi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sukeno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iizuka-Ohashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sowa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The Pleiotropic Regulation of Cyclin D1 by Newly Identified Sesaminol-Binding Protein ANT2</article-title>. <source>Oncogenesis</source> <volume>6</volume>, <fpage>e311</fpage>. <pub-id pub-id-type="doi">10.1038/oncsis.2017.10</pub-id> </citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woo</surname>
<given-names>P. C. Y.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>S. K. P.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>C.-m.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K.-h.</given-names>
</name>
<name>
<surname>Tsoi</surname>
<given-names>H.-w.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia</article-title>. <source>J.&#x20;Virol.</source> <volume>79</volume>, <fpage>884</fpage>&#x2013;<lpage>895</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.79.2.884-895.2005</pub-id> </citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China</article-title>. <source>Cell Host Microbe</source> <volume>27</volume>, <fpage>325</fpage>&#x2013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2020.02.001</pub-id> </citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.-S.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>Y.-J.</given-names>
</name>
</person-group> (<year>2020b</year>). <article-title>The Outbreak of COVID-19: An Overview</article-title>. <source>J.&#x20;Chin. Med. Assoc.</source> <volume>83</volume>, <fpage>217</fpage>&#x2013;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1097/jcma.0000000000000270</pub-id> </citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>McGoogan</surname>
<given-names>J.&#x20;M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China</article-title>. <source>JAMA</source> <volume>323</volume>, <fpage>1239</fpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id> </citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.-W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.-X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.-G.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>K.-J.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>L.-J.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C.-L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Clinical Findings in a Group of Patients Infected with the 2019 Novel Coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective Case Series</article-title>. <source>BMJ</source> <volume>368</volume>, <fpage>m606</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m606</pub-id> </citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Severe Acute Respiratory Syndrome Coronavirus 2-induced Neurological Complications</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>8</volume>, <fpage>8</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2020.605972</pub-id> </citation>
</ref>
<ref id="B119">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>MacKerell</surname>
<given-names>A. D.</given-names>
</name>
</person-group> (<year>2016</year>). &#x201c;<article-title>Computer-Aided Drug Design Methods</article-title>,&#x201d; in <source>Methods in Molecular Biology</source>. (<publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>85</fpage>&#x2013;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-6634-9_5</pub-id> </citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Patients with COVID-19 in 19 ICUs in Wuhan, China: a Cross-Sectional Study</article-title>. <source>Crit. Care</source> <volume>24</volume>, <fpage>219</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-02939-x</pub-id> </citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>N. C.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.-C. D. D.</given-names>
</name>
<name>
<surname>So</surname>
<given-names>R. T. Y.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Highly Conserved Cryptic Epitope in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV</article-title>. <source>Science</source> <volume>368</volume>, <fpage>630</fpage>&#x2013;<lpage>633</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb7269</pub-id> </citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Curth</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Drosten</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sauerhering</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved &#x3b1;-ketoamide Inhibitors</article-title>. <source>Science</source> <volume>368</volume>, <fpage>409</fpage>&#x2013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb3405</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>